SamYYL的个人主页 - 老虎社区

SamYYL

SamYYL

暂无个人介绍

IP属地：海外

202关注

76粉丝

0主题

0勋章

2021-11-28

Like

US IPO Week Ahead: December kicks off with a 1 IPO week<blockquote>美国 IPO 周即将到来：12 月以 1 IPO 周拉开帷幕</blockquote>

2021-11-01

Good and like

5 Stocks To Watch For November 1, 2021<blockquote>2021 年 11 月 1 日值得关注的 5 只股票</blockquote>

2021-11-28

Good and like

抱歉，原内容已删除

2021-09-27

Good and like

抱歉，原内容已删除

2021-11-18

Like

抱歉，原内容已删除

2021-10-06

Good and like

抱歉，原内容已删除

2021-09-10

Like

抱歉，原内容已删除

2021-11-15

Good and like

抱歉，原内容已删除

2021-10-31

Like

5 Stocks For Halloween: Will They Be Tricks Or Treats?<blockquote>万圣节的5只股票：它们会是骗局还是款待？</blockquote>

2021-10-18

Good and like

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4089205014499330","uuid":"4089205014499330","gmtCreate":1626105994923,"gmtModify":1628260928299,"name":"SamYYL","pinyin":"samyyl","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":76,"headSize":202,"tweetSize":252,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.24","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.08.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"海外","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":471787221598456,"gmtCreate":1756214263982,"gmtModify":1756214264855,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/YALA\">$Yalla Group(YALA)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://laohu8.com/S/YALA\">$Yalla Group(YALA)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$Yalla Group(YALA)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/471787221598456","isVote":1,"tweetType":1,"viewCount":2209,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":470409354842672,"gmtCreate":1755877619936,"gmtModify":1755877620695,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/YALA\">$Yalla Group(YALA)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://laohu8.com/S/YALA\">$Yalla Group(YALA)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$Yalla Group(YALA)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/470409354842672","isVote":1,"tweetType":1,"viewCount":1824,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":460234364707600,"gmtCreate":1753371186741,"gmtModify":1753371187608,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/YALA\">$Yalla Group(YALA)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://laohu8.com/S/YALA\">$Yalla Group(YALA)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$Yalla Group(YALA)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/460234364707600","isVote":1,"tweetType":1,"viewCount":2155,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":459266906509928,"gmtCreate":1753162397433,"gmtModify":1753162398207,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/YALA\">$Yalla Group(YALA)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://laohu8.com/S/YALA\">$Yalla Group(YALA)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$Yalla Group(YALA)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/459266906509928","isVote":1,"tweetType":1,"viewCount":2026,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":694704798,"gmtCreate":1642111190317,"gmtModify":1642111191069,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/694704798","repostId":"1138592368","repostType":4,"isVote":1,"tweetType":1,"viewCount":4035,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694532964,"gmtCreate":1642040826583,"gmtModify":1642040827391,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Good and like&nbsp;","listText":"Good and like&nbsp;","text":"Good and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/694532964","repostId":"2201214004","repostType":4,"isVote":1,"tweetType":1,"viewCount":3633,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694536463,"gmtCreate":1642040803790,"gmtModify":1642040804632,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/694536463","repostId":"1134509683","repostType":4,"repost":{"id":"1134509683","kind":"news","pubTimestamp":1641612579,"share":"https://www.laohunote.com/m/news/1134509683?lang=zh_CN&edition=full","pubTime":"2022-01-08 11:29","market":"us","language":"en","title":"3 COVID Stocks That Will Make Billions in 2022<blockquote>2022 年将赚取数十亿美元的 3 只新冠股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1134509683","media":"Motley Fool","summary":"These three COVID-19 stocks could rake in a tremendous amount of cash this year.","content":"<p><html><head></head><body>It&#39;s a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.</p><p><blockquote><html><head></head><body>新的一年了，新冠肺炎仍然和我们在一起。去年，我们看到了医疗保健领域多种COVID疫苗和治疗的紧急使用授权。制药公司将在 2022 年赚取数十亿美元。以下是三只应该蓬勃发展的股票。</body></html></blockquote></p><p><b>Pfizer</b>(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy <b>Novavax</b>(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in <b>Vir Biotechnology</b>(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.</p><p><blockquote><b>辉瑞</b>（纽约证券交易所股票代码：PFE）是一家价值 3100 亿美元的巨型公司，预计其新冠疫苗和抗病毒药丸的销售额将不是 10 亿美元或 100 亿美元，而是超过 500 亿美元。好斗<b>诺瓦瓦克斯</b>（纳斯达克股票代码：NVAX）终于在世界各地推出了新冠疫苗。它将获得多少亿？我们有一个黑马候选人<b>生物技术</b>（纳斯达克股票代码：VIR）它有一种药物很容易成为小型生物技术公司10亿美元的重磅炸弹。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/488a166201699c1f3d6536aa3e640ecf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p><b>A safe harbor in stormy weather</b></p><p><blockquote><b>暴风雨天气中的安全港湾</b></blockquote></p><p><b>George Budwell(Pfizer):</b>Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.</p><p><blockquote><b>乔治·布德威尔（辉瑞）：</b>辉瑞是新冠肺炎药品无可争议的冠军。仅在 2022 年，华尔街预计这家制药巨头的新型冠状病毒疫苗 Comirnaty 和口服抗病毒药 Paxlovid 的销售额将达到 550 亿美元。</blockquote></p><p>What&#39;s more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.</p><p><blockquote>更重要的是，分析师开始接受 Paxlovid 可能成为该公司当前十年可持续收入来源的想法。上个月，当美国食品药品监督管理局根据紧急使用授权途径首次允许该药物投放市场时，华尔街认为 Paxlovid 可能会在一年左右的时间内达到商业顶峰，然后随着疫情淡出视野，销售额将大幅下降。</blockquote></p><p>But less than three weeks out from the drug&#39;s initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.</p><p><blockquote>但距离该药物首次批准还有不到三周的时间，很明显，Paxlovid 可能会在未来几年内被用作防止 COVID-19 最糟糕后果的故障安全药物。毕竟，高度传染性的奥密克戎变种肯定不会是该病毒的最后一次重大迭代。</blockquote></p><p>What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.</p><p><blockquote>这一切意味着辉瑞应该是少数几家拥有可观的长期 COVID-19 收入来源的大型制药商之一。反过来，辉瑞应该有充足的自由现金流来满足其慷慨的股东奖励计划以及在可预见的未来雄心勃勃的业务发展计划。</blockquote></p><p>So, if you&#39;re looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.</p><p><blockquote>因此，如果您正在寻找一只能够经受住高通胀和利率上升双重阻力的股票，辉瑞可能值得一看。</blockquote></p><p><b>Revenue forecasts for Novavax:  $2 billion to $8 billion</b></p><p><blockquote><b>Novavax 收入预测：20 亿至 80 亿美元</b></blockquote></p><p><b>Taylor Carmichael(Novavax):</b>Novavax is on the verge of greatness this year. The company&#39;s stock price is down to $125 a share. That&#39;s where it started in 2021, so last year was pretty much a washout for the stock.</p><p><blockquote><b>泰勒·卡迈克尔（诺瓦瓦克斯）：</b>Novavax 今年正处于伟大的边缘。该公司股价跌至每股 125 美元。这就是它在 2021 年开始的地方，所以去年对于该股来说几乎是一次洗牌。</blockquote></p><p>Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.</p><p><blockquote>早在 2 月份，当 Novavax 报告其 COVID 疫苗的 3 期数据积极时，股价就飙升至 300 美元以上。但后来这家小型生物技术公司遇到了制造问题。虽然许多人称其疫苗是同类产品中最好的，但扩大约 20 亿剂疫苗的合同生产规模说起来容易做起来难。这些现实导致该股从高点下跌了约 60%。</blockquote></p><p>Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it&#39;s highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company&#39;s already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.</p><p><blockquote>尽管如此，Novavax 的收入已经达到了 10 亿美元大关，因此由于所有的预购，其疫苗甚至在获得批准之前就已经大受欢迎。现在，来自全球各地的授权纷至沓来，Novavax很有可能在2022年运送大量疫苗剂量。该公司已经实现了每月1亿剂的生产能力，即一年12亿剂。在第三季度财报看涨期权上，管理层预测到第四季度末将达到每月1.5亿剂（或每年18亿剂）的产能。该公司预计将继续扩大规模，并预测 2022 年将分发 20 亿剂疫苗。</blockquote></p><p>Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that&#39;s over $4 billion in sales, just in Europe.</p><p><blockquote>20亿剂疫苗，价格为16美元（曲速行动支付了16亿美元预购1亿剂），我们得到了320亿美元的收入。当然，Novavax将以较低的速度向发展中国家分发大量疫苗。虽然该公司对其价格保持沉默，但丹麦早在 8 月份就表示，根据欧盟 (EU) 协议，它每剂支付了近 21 美元。欧盟已经订购了2亿剂，仅在欧洲的销售额就超过了40亿美元。</blockquote></p><p></p><p>Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company&#39;s market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.</p><p><blockquote>分析师极其保守，预测 Novavax 2022 年的市值在 20 亿至 80 亿美元之间。（该公司的市值为 90 亿美元。）虽然一路上可能会出现一些小问题，但 Novavax 肯定会在 2022 年从其 COVID-19 疫苗中赚取数十亿美元。如果该公司确实像所说的那样交付了 20 亿剂疫苗，那么该股可能会有显着的上涨空间。</blockquote></p><p><b>The antibody market all to itself</b></p><p><blockquote><b>抗体市场本身</b></blockquote></p><p><b>Patrick Bafuma(Vir Biotechnology):</b>The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from <b>Eli Lilly</b> (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from <b>Roche</b>and<b>Regeneron</b> are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--<b>GlaxoSmithKline</b> and Vir Biotechnology&#39;s sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it&#39;s the only one left right now to fight the omicron variant.</p><p><blockquote><b>Patrick Bafuma（来自生物技术）：</b>奥密克戎变种目前正在猖獗，这一次，我们缺少一些治疗方法。以前青睐的单克隆抗体治疗来自<b>礼来</b>（bamlanivimab加etesevimab）以及来自<b>罗氏</b>和<b>再生元</b>被认为对当前变体的活性明显减弱。这样就只剩下一个能有效对抗奥密克戎--<b>葛兰素史克</b>以及 Vir Biotechnology 的 sotrovimab。这种单克隆抗体此前已证明，患有轻度至中度 COVID-19 且有发展为严重疾病高风险的成年人的住院和死亡风险降低了 79%。这是现在唯一一个对抗奥密克戎变种的人。</blockquote></p><p>Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly&#39;s antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.</p><p><blockquote>作为该区块上唯一的单克隆抗体将有其特权。2021 年前 9 个月，REGEN-COV 带来了 35 亿美元的产品净销售额，而礼来公司的抗体组合带来了 11.7 亿美元的收入。美国政府已经签订了价值约10亿美元的sotrovimab合同。随着医院里挤满了病人，任何有助于减轻系统压力的东西都可能会受到高度追捧。</blockquote></p><p>And while Pfizer&#39;s Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who&#39;s who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid&#39;s possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.</p><p><blockquote>虽然辉瑞的 Paxlovid 将极大地有助于减轻 COVID-19 对医疗保健系统的负担，但口服药物具有显着且复杂的药物相互作用潜力。事实上，它的相互作用列表读起来就像常用处方药物的名人录。这包括流行的血液稀释剂，如波立维和Xarelto，常见的镇痛药，如曲马多和羟考酮，抗焦虑药，如Klonopin和Xanax，以及抗胆固醇他汀类药物。随着美国国立卫生研究院发表声明，对Paxlovid可能的药物相互作用表示担忧，这为sotrovimab继续广泛使用留下了足够的空间。根据与葛兰素史克的协议，Vir 获得了 sotrovimab 72.5% 的销售额，这家价值 44 亿美元的生物技术公司目前看起来很划算。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Will Make Billions in 2022<blockquote>2022 年将赚取数十亿美元的 3 只新冠股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Will Make Billions in 2022<blockquote>2022 年将赚取数十亿美元的 3 只新冠股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2022-01-08 11:29</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>It&#39;s a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.</p><p><blockquote><html><head></head><body>新的一年了，新冠肺炎仍然和我们在一起。去年，我们看到了医疗保健领域多种COVID疫苗和治疗的紧急使用授权。制药公司将在 2022 年赚取数十亿美元。以下是三只应该蓬勃发展的股票。</body></html></blockquote></p><p><b>Pfizer</b>(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy <b>Novavax</b>(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in <b>Vir Biotechnology</b>(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.</p><p><blockquote><b>辉瑞</b>（纽约证券交易所股票代码：PFE）是一家价值 3100 亿美元的巨型公司，预计其新冠疫苗和抗病毒药丸的销售额将不是 10 亿美元或 100 亿美元，而是超过 500 亿美元。好斗<b>诺瓦瓦克斯</b>（纳斯达克股票代码：NVAX）终于在世界各地推出了新冠疫苗。它将获得多少亿？我们有一个黑马候选人<b>生物技术</b>（纳斯达克股票代码：VIR）它有一种药物很容易成为小型生物技术公司10亿美元的重磅炸弹。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/488a166201699c1f3d6536aa3e640ecf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p><b>A safe harbor in stormy weather</b></p><p><blockquote><b>暴风雨天气中的安全港湾</b></blockquote></p><p><b>George Budwell(Pfizer):</b>Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.</p><p><blockquote><b>乔治·布德威尔（辉瑞）：</b>辉瑞是新冠肺炎药品无可争议的冠军。仅在 2022 年，华尔街预计这家制药巨头的新型冠状病毒疫苗 Comirnaty 和口服抗病毒药 Paxlovid 的销售额将达到 550 亿美元。</blockquote></p><p>What&#39;s more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.</p><p><blockquote>更重要的是，分析师开始接受 Paxlovid 可能成为该公司当前十年可持续收入来源的想法。上个月，当美国食品药品监督管理局根据紧急使用授权途径首次允许该药物投放市场时，华尔街认为 Paxlovid 可能会在一年左右的时间内达到商业顶峰，然后随着疫情淡出视野，销售额将大幅下降。</blockquote></p><p>But less than three weeks out from the drug&#39;s initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.</p><p><blockquote>但距离该药物首次批准还有不到三周的时间，很明显，Paxlovid 可能会在未来几年内被用作防止 COVID-19 最糟糕后果的故障安全药物。毕竟，高度传染性的奥密克戎变种肯定不会是该病毒的最后一次重大迭代。</blockquote></p><p>What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.</p><p><blockquote>这一切意味着辉瑞应该是少数几家拥有可观的长期 COVID-19 收入来源的大型制药商之一。反过来，辉瑞应该有充足的自由现金流来满足其慷慨的股东奖励计划以及在可预见的未来雄心勃勃的业务发展计划。</blockquote></p><p>So, if you&#39;re looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.</p><p><blockquote>因此，如果您正在寻找一只能够经受住高通胀和利率上升双重阻力的股票，辉瑞可能值得一看。</blockquote></p><p><b>Revenue forecasts for Novavax:  $2 billion to $8 billion</b></p><p><blockquote><b>Novavax 收入预测：20 亿至 80 亿美元</b></blockquote></p><p><b>Taylor Carmichael(Novavax):</b>Novavax is on the verge of greatness this year. The company&#39;s stock price is down to $125 a share. That&#39;s where it started in 2021, so last year was pretty much a washout for the stock.</p><p><blockquote><b>泰勒·卡迈克尔（诺瓦瓦克斯）：</b>Novavax 今年正处于伟大的边缘。该公司股价跌至每股 125 美元。这就是它在 2021 年开始的地方，所以去年对于该股来说几乎是一次洗牌。</blockquote></p><p>Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.</p><p><blockquote>早在 2 月份，当 Novavax 报告其 COVID 疫苗的 3 期数据积极时，股价就飙升至 300 美元以上。但后来这家小型生物技术公司遇到了制造问题。虽然许多人称其疫苗是同类产品中最好的，但扩大约 20 亿剂疫苗的合同生产规模说起来容易做起来难。这些现实导致该股从高点下跌了约 60%。</blockquote></p><p>Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it&#39;s highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company&#39;s already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.</p><p><blockquote>尽管如此，Novavax 的收入已经达到了 10 亿美元大关，因此由于所有的预购，其疫苗甚至在获得批准之前就已经大受欢迎。现在，来自全球各地的授权纷至沓来，Novavax很有可能在2022年运送大量疫苗剂量。该公司已经实现了每月1亿剂的生产能力，即一年12亿剂。在第三季度财报看涨期权上，管理层预测到第四季度末将达到每月1.5亿剂（或每年18亿剂）的产能。该公司预计将继续扩大规模，并预测 2022 年将分发 20 亿剂疫苗。</blockquote></p><p>Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that&#39;s over $4 billion in sales, just in Europe.</p><p><blockquote>20亿剂疫苗，价格为16美元（曲速行动支付了16亿美元预购1亿剂），我们得到了320亿美元的收入。当然，Novavax将以较低的速度向发展中国家分发大量疫苗。虽然该公司对其价格保持沉默，但丹麦早在 8 月份就表示，根据欧盟 (EU) 协议，它每剂支付了近 21 美元。欧盟已经订购了2亿剂，仅在欧洲的销售额就超过了40亿美元。</blockquote></p><p></p><p>Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company&#39;s market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.</p><p><blockquote>分析师极其保守，预测 Novavax 2022 年的市值在 20 亿至 80 亿美元之间。（该公司的市值为 90 亿美元。）虽然一路上可能会出现一些小问题，但 Novavax 肯定会在 2022 年从其 COVID-19 疫苗中赚取数十亿美元。如果该公司确实像所说的那样交付了 20 亿剂疫苗，那么该股可能会有显着的上涨空间。</blockquote></p><p><b>The antibody market all to itself</b></p><p><blockquote><b>抗体市场本身</b></blockquote></p><p><b>Patrick Bafuma(Vir Biotechnology):</b>The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from <b>Eli Lilly</b> (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from <b>Roche</b>and<b>Regeneron</b> are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--<b>GlaxoSmithKline</b> and Vir Biotechnology&#39;s sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it&#39;s the only one left right now to fight the omicron variant.</p><p><blockquote><b>Patrick Bafuma（来自生物技术）：</b>奥密克戎变种目前正在猖獗，这一次，我们缺少一些治疗方法。以前青睐的单克隆抗体治疗来自<b>礼来</b>（bamlanivimab加etesevimab）以及来自<b>罗氏</b>和<b>再生元</b>被认为对当前变体的活性明显减弱。这样就只剩下一个能有效对抗奥密克戎--<b>葛兰素史克</b>以及 Vir Biotechnology 的 sotrovimab。这种单克隆抗体此前已证明，患有轻度至中度 COVID-19 且有发展为严重疾病高风险的成年人的住院和死亡风险降低了 79%。这是现在唯一一个对抗奥密克戎变种的人。</blockquote></p><p>Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly&#39;s antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.</p><p><blockquote>作为该区块上唯一的单克隆抗体将有其特权。2021 年前 9 个月，REGEN-COV 带来了 35 亿美元的产品净销售额，而礼来公司的抗体组合带来了 11.7 亿美元的收入。美国政府已经签订了价值约10亿美元的sotrovimab合同。随着医院里挤满了病人，任何有助于减轻系统压力的东西都可能会受到高度追捧。</blockquote></p><p>And while Pfizer&#39;s Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who&#39;s who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid&#39;s possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.</p><p><blockquote>虽然辉瑞的 Paxlovid 将极大地有助于减轻 COVID-19 对医疗保健系统的负担，但口服药物具有显着且复杂的药物相互作用潜力。事实上，它的相互作用列表读起来就像常用处方药物的名人录。这包括流行的血液稀释剂，如波立维和Xarelto，常见的镇痛药，如曲马多和羟考酮，抗焦虑药，如Klonopin和Xanax，以及抗胆固醇他汀类药物。随着美国国立卫生研究院发表声明，对Paxlovid可能的药物相互作用表示担忧，这为sotrovimab继续广泛使用留下了足够的空间。根据与葛兰素史克的协议，Vir 获得了 sotrovimab 72.5% 的销售额，这家价值 44 亿美元的生物技术公司目前看起来很划算。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","VIR":"Vir Biotechnology, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134509683","content_text":"It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.Pfizer(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy Novavax(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in Vir Biotechnology(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.IMAGE SOURCE: GETTY IMAGES.A safe harbor in stormy weatherGeorge Budwell(Pfizer):Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.What's more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.But less than three weeks out from the drug's initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.So, if you're looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.Revenue forecasts for Novavax:  $2 billion to $8 billionTaylor Carmichael(Novavax):Novavax is on the verge of greatness this year. The company's stock price is down to $125 a share. That's where it started in 2021, so last year was pretty much a washout for the stock.Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it's highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company's already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that's over $4 billion in sales, just in Europe.Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company's market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.The antibody market all to itselfPatrick Bafuma(Vir Biotechnology):The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from Eli Lilly (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from RocheandRegeneron are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--GlaxoSmithKline and Vir Biotechnology's sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it's the only one left right now to fight the omicron variant.Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly's antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.And while Pfizer's Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who's who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid's possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.","news_type":1,"symbols_score_info":{"NVAX":0.9,"PFE":0.9,"VIR":0.9}},"isVote":1,"tweetType":1,"viewCount":3258,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694536582,"gmtCreate":1642040783809,"gmtModify":1642040784566,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Good and like&nbsp;","listText":"Good and like&nbsp;","text":"Good and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/694536582","repostId":"1162390026","repostType":4,"isVote":1,"tweetType":1,"viewCount":3446,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694538332,"gmtCreate":1642040436902,"gmtModify":1642040437726,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Good and like&nbsp;","listText":"Good and like&nbsp;","text":"Good and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/694538332","repostId":"1198290127","repostType":4,"repost":{"id":"1198290127","kind":"news","pubTimestamp":1641702682,"share":"https://www.laohunote.com/m/news/1198290127?lang=zh_CN&edition=full","pubTime":"2022-01-09 12:31","market":"us","language":"en","title":"Can Apple Stock Reclaim $3 Trillion And Thrive In 2022?<blockquote>苹果股票能否在2022年收回3万亿美元并蓬勃发展？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1198290127","media":"TheStreet","summary":"A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready","content":"<p><html><head></head><body>A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready to break through yet. Can shares reclaim the milestone soon and head higher in 2022?</p><p><blockquote><html><head></head><body>到目前为止，3 万亿美元的市值已被证明是苹果股票似乎尚未准备好突破的上限。股价能否很快夺回里程碑并在 2022 年走高？</body></html></blockquote></p><p>Recently, Apple stock flirted with $3 trillion in market cap, but quickly dipped below $2.9 trillion — as the broad market reacted to monetary tightening that should now happen more rapidly than previously expected.</p><p><blockquote>最近，苹果股票的市值接近 3 万亿美元，但很快跌破 2.9 万亿美元——因为大盘对货币紧缩政策的反应应该比之前预期的更快。</blockquote></p><p>Can shares of the Cupertino company finally find its way north in 2022 and meet the expectations of so many bulls on Wall Street? Or will bearishness take over during a year of rising interest rates and lingering inflation?</p><p><blockquote>这家库比蒂诺公司的股票最终能否在 2022 年找到北上之路，并满足华尔街众多多头的期望？或者，在利率上升和通胀挥之不去的一年里，看跌情绪会接管吗？</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1f77cd919bf55f9c7b79f631b0255910\" tg-width=\"1240\" tg-height=\"697\" referrerpolicy=\"no-referrer\"/><span>Figure 1: Apple Park in Cupertino, CA.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：加利福尼亚州库比蒂诺的苹果公园。</span></p></blockquote></p><p><b>AAPL: the bull case</b></p><p><blockquote><b>AAPL：牛市案例</b></blockquote></p><p>As Apple stock climbed viciously between late November and early December, many Wall Street experts piled on in support of “AAPL $3T”. Wedbush’s Dan Ives, for example, has been talking about the market cap milestone since our conversation in Q3 of last year, at least.</p><p><blockquote>随着苹果股价在 11 月底至 12 月初疯狂攀升，许多华尔街专家纷纷支持 “AAPL 3 万亿美元 ”。例如，至少从我们去年第三季度的谈话开始，Wedbush 的丹-艾夫斯（Dan Ives）就一直在谈论市值里程碑。</blockquote></p><p>But other analysts have also hopped on the bullish bandwagon recently. Morgan Stanley upped its price target to $200 per share in November, while the JPMorgan research team saw Apple stock heading to $3.5 trillion in market cap over the next 12 months.</p><p><blockquote>但其他分析师最近也加入了看涨行列。摩根士丹利在 11 月份将目标价上调至每股 200 美元，而摩根大通研究团队则预计苹果股票在未来 12 个月内市值将达到 3.5 万亿美元。</blockquote></p><p>One of the most vocal optimists came from the buy side. Loup’s Gene Munster thought that his previous price target had quickly become stale, and that $250 per share now seemed more reasonable. In his opinion, the multi-year opportunity in the metaverse will gain investor appreciation in the new year, which should reignite momentum that the stock had lost in the last few weeks of 2021.</p><p><blockquote>最直言不讳的乐观主义者之一来自买方。Loup 的吉恩-明斯特（Gene Munster）认为，他之前的目标价很快就过时了，现在每股 250 美元似乎更合理。他认为，元宇宙的多年机会将在新的一年获得投资者的赞赏，这应该会重新点燃该股在2021年最后几周失去的势头。</blockquote></p><p><b>AAPL: the bear case</b></p><p><blockquote><b>AAPL：熊案</b></blockquote></p><p>Despite the upbeat expectations described above, mostly supported by company-specific factors, the market rolled into 2022 with its guard up. The boogieman of the moment seems to be the Federal Reserve’s anticipated reaction to near-full employment and sticky inflation, which should lead to higher interest rates in the next several months.</p><p><blockquote>尽管上述乐观预期主要受到公司特定因素的支持，但市场进入 2022 年仍保持警惕。目前的祸根似乎是美联储对接近充分就业和粘性通胀的预期反应，这将导致未来几个月利率上升。</blockquote></p><p>I have recently explained how tighter money supply can spell trouble for stocks that trade for relatively high multiples. While AAPL is no Tesla or Rivian, the stock’s forward P/E of nearly 30 times and only modest earnings growth expectations could be a drag for share price in 2022, as investors look for better deals in value and cyclical stocks.</p><p><blockquote>我最近解释了货币供应收紧如何给市盈率相对较高的股票带来麻烦。虽然 AAPL 不是特斯拉或Rivian，但该股近 30 倍的远期市盈率和温和的盈利增长预期可能会拖累 2022 年的股价，因为投资者正在寻找价值股和周期性股票的更好交易。</blockquote></p><p><b>The Apple Maven’s take</b></p><p><blockquote><b>苹果专家的看法</b></blockquote></p><p>I continue to think that Apple is a great stock to buy and hold for the long term. Under the leadership of a CEO (and former COO) that is driven by operational excellence, the company seems to be in very good hands. Better yet, demand for Apple’s products and services, as well as consumer appreciation for the brand, seem to be at or near an all-time high.</p><p><blockquote>我仍然认为苹果是一只值得长期购买和持有的好股票。在以卓越运营为动力的首席执行官（兼前首席运营官）的领导下，公司似乎得到了很好的管理。更好的是，对苹果产品和服务的需求以及消费者对该品牌的欣赏似乎处于或接近历史最高水平。</blockquote></p><p>That said, the setup for the first few weeks or months of 2022 looks challenging to me. Apple stock climbed relentlessly in 2020, and then again last year. Aided by a spike in pandemic-driven demand for tech devices and lavish liquidity in the system, AAPL recorded one of its best three years of returns ever between 2019 and 2021.</p><p><blockquote>也就是说，2022 年头几周或几个月的设置对我来说很有挑战性。苹果股价在 2020 年持续攀升，去年又再次攀升。得益于疫情推动的技术设备需求激增以及系统中充足的流动性，苹果公司在 2019 年至 2021 年间创下了有史以来最好的三年回报之一。</blockquote></p><p>As much as the metaverse and autonomous vehicles can and likely will support the company’s financial results over the next many years, I think that AAPL stock is overdue for a breather. While shares will likely climb back above $3 trillion and head much higher from there eventually, I am not so confident that this rally will happen in the immediate future.</p><p><blockquote>尽管元宇宙和自动驾驶汽车能够并可能在未来许多年为公司的财务业绩提供支持，但我认为苹果公司的股票早该喘口气了。虽然股价可能会回升至 3 万亿美元以上，并最终从那里走得更高，但我对这种反弹会在不久的将来发生并不那么有信心。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can Apple Stock Reclaim $3 Trillion And Thrive In 2022?<blockquote>苹果股票能否在2022年收回3万亿美元并蓬勃发展？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan Apple Stock Reclaim $3 Trillion And Thrive In 2022?<blockquote>苹果股票能否在2022年收回3万亿美元并蓬勃发展？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2022-01-09 12:31</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready to break through yet. Can shares reclaim the milestone soon and head higher in 2022?</p><p><blockquote><html><head></head><body>到目前为止，3 万亿美元的市值已被证明是苹果股票似乎尚未准备好突破的上限。股价能否很快夺回里程碑并在 2022 年走高？</body></html></blockquote></p><p>Recently, Apple stock flirted with $3 trillion in market cap, but quickly dipped below $2.9 trillion — as the broad market reacted to monetary tightening that should now happen more rapidly than previously expected.</p><p><blockquote>最近，苹果股票的市值接近 3 万亿美元，但很快跌破 2.9 万亿美元——因为大盘对货币紧缩政策的反应应该比之前预期的更快。</blockquote></p><p>Can shares of the Cupertino company finally find its way north in 2022 and meet the expectations of so many bulls on Wall Street? Or will bearishness take over during a year of rising interest rates and lingering inflation?</p><p><blockquote>这家库比蒂诺公司的股票最终能否在 2022 年找到北上之路，并满足华尔街众多多头的期望？或者，在利率上升和通胀挥之不去的一年里，看跌情绪会接管吗？</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1f77cd919bf55f9c7b79f631b0255910\" tg-width=\"1240\" tg-height=\"697\" referrerpolicy=\"no-referrer\"/><span>Figure 1: Apple Park in Cupertino, CA.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：加利福尼亚州库比蒂诺的苹果公园。</span></p></blockquote></p><p><b>AAPL: the bull case</b></p><p><blockquote><b>AAPL：牛市案例</b></blockquote></p><p>As Apple stock climbed viciously between late November and early December, many Wall Street experts piled on in support of “AAPL $3T”. Wedbush’s Dan Ives, for example, has been talking about the market cap milestone since our conversation in Q3 of last year, at least.</p><p><blockquote>随着苹果股价在 11 月底至 12 月初疯狂攀升，许多华尔街专家纷纷支持 “AAPL 3 万亿美元 ”。例如，至少从我们去年第三季度的谈话开始，Wedbush 的丹-艾夫斯（Dan Ives）就一直在谈论市值里程碑。</blockquote></p><p>But other analysts have also hopped on the bullish bandwagon recently. Morgan Stanley upped its price target to $200 per share in November, while the JPMorgan research team saw Apple stock heading to $3.5 trillion in market cap over the next 12 months.</p><p><blockquote>但其他分析师最近也加入了看涨行列。摩根士丹利在 11 月份将目标价上调至每股 200 美元，而摩根大通研究团队则预计苹果股票在未来 12 个月内市值将达到 3.5 万亿美元。</blockquote></p><p>One of the most vocal optimists came from the buy side. Loup’s Gene Munster thought that his previous price target had quickly become stale, and that $250 per share now seemed more reasonable. In his opinion, the multi-year opportunity in the metaverse will gain investor appreciation in the new year, which should reignite momentum that the stock had lost in the last few weeks of 2021.</p><p><blockquote>最直言不讳的乐观主义者之一来自买方。Loup 的吉恩-明斯特（Gene Munster）认为，他之前的目标价很快就过时了，现在每股 250 美元似乎更合理。他认为，元宇宙的多年机会将在新的一年获得投资者的赞赏，这应该会重新点燃该股在2021年最后几周失去的势头。</blockquote></p><p><b>AAPL: the bear case</b></p><p><blockquote><b>AAPL：熊案</b></blockquote></p><p>Despite the upbeat expectations described above, mostly supported by company-specific factors, the market rolled into 2022 with its guard up. The boogieman of the moment seems to be the Federal Reserve’s anticipated reaction to near-full employment and sticky inflation, which should lead to higher interest rates in the next several months.</p><p><blockquote>尽管上述乐观预期主要受到公司特定因素的支持，但市场进入 2022 年仍保持警惕。目前的祸根似乎是美联储对接近充分就业和粘性通胀的预期反应，这将导致未来几个月利率上升。</blockquote></p><p>I have recently explained how tighter money supply can spell trouble for stocks that trade for relatively high multiples. While AAPL is no Tesla or Rivian, the stock’s forward P/E of nearly 30 times and only modest earnings growth expectations could be a drag for share price in 2022, as investors look for better deals in value and cyclical stocks.</p><p><blockquote>我最近解释了货币供应收紧如何给市盈率相对较高的股票带来麻烦。虽然 AAPL 不是特斯拉或Rivian，但该股近 30 倍的远期市盈率和温和的盈利增长预期可能会拖累 2022 年的股价，因为投资者正在寻找价值股和周期性股票的更好交易。</blockquote></p><p><b>The Apple Maven’s take</b></p><p><blockquote><b>苹果专家的看法</b></blockquote></p><p>I continue to think that Apple is a great stock to buy and hold for the long term. Under the leadership of a CEO (and former COO) that is driven by operational excellence, the company seems to be in very good hands. Better yet, demand for Apple’s products and services, as well as consumer appreciation for the brand, seem to be at or near an all-time high.</p><p><blockquote>我仍然认为苹果是一只值得长期购买和持有的好股票。在以卓越运营为动力的首席执行官（兼前首席运营官）的领导下，公司似乎得到了很好的管理。更好的是，对苹果产品和服务的需求以及消费者对该品牌的欣赏似乎处于或接近历史最高水平。</blockquote></p><p>That said, the setup for the first few weeks or months of 2022 looks challenging to me. Apple stock climbed relentlessly in 2020, and then again last year. Aided by a spike in pandemic-driven demand for tech devices and lavish liquidity in the system, AAPL recorded one of its best three years of returns ever between 2019 and 2021.</p><p><blockquote>也就是说，2022 年头几周或几个月的设置对我来说很有挑战性。苹果股价在 2020 年持续攀升，去年又再次攀升。得益于疫情推动的技术设备需求激增以及系统中充足的流动性，苹果公司在 2019 年至 2021 年间创下了有史以来最好的三年回报之一。</blockquote></p><p>As much as the metaverse and autonomous vehicles can and likely will support the company’s financial results over the next many years, I think that AAPL stock is overdue for a breather. While shares will likely climb back above $3 trillion and head much higher from there eventually, I am not so confident that this rally will happen in the immediate future.</p><p><blockquote>尽管元宇宙和自动驾驶汽车能够并可能在未来许多年为公司的财务业绩提供支持，但我认为苹果公司的股票早该喘口气了。虽然股价可能会回升至 3 万亿美元以上，并最终从那里走得更高，但我对这种反弹会在不久的将来发生并不那么有信心。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/apple/stock/can-apple-stock-reclaim-3-trillion-and-thrive-in-2022\">TheStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/apple/stock/can-apple-stock-reclaim-3-trillion-and-thrive-in-2022","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198290127","content_text":"A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready to break through yet. Can shares reclaim the milestone soon and head higher in 2022?Recently, Apple stock flirted with $3 trillion in market cap, but quickly dipped below $2.9 trillion — as the broad market reacted to monetary tightening that should now happen more rapidly than previously expected.Can shares of the Cupertino company finally find its way north in 2022 and meet the expectations of so many bulls on Wall Street? Or will bearishness take over during a year of rising interest rates and lingering inflation?Figure 1: Apple Park in Cupertino, CA.AAPL: the bull caseAs Apple stock climbed viciously between late November and early December, many Wall Street experts piled on in support of “AAPL $3T”. Wedbush’s Dan Ives, for example, has been talking about the market cap milestone since our conversation in Q3 of last year, at least.But other analysts have also hopped on the bullish bandwagon recently. Morgan Stanley upped its price target to $200 per share in November, while the JPMorgan research team saw Apple stock heading to $3.5 trillion in market cap over the next 12 months.One of the most vocal optimists came from the buy side. Loup’s Gene Munster thought that his previous price target had quickly become stale, and that $250 per share now seemed more reasonable. In his opinion, the multi-year opportunity in the metaverse will gain investor appreciation in the new year, which should reignite momentum that the stock had lost in the last few weeks of 2021.AAPL: the bear caseDespite the upbeat expectations described above, mostly supported by company-specific factors, the market rolled into 2022 with its guard up. The boogieman of the moment seems to be the Federal Reserve’s anticipated reaction to near-full employment and sticky inflation, which should lead to higher interest rates in the next several months.I have recently explained how tighter money supply can spell trouble for stocks that trade for relatively high multiples. While AAPL is no Tesla or Rivian, the stock’s forward P/E of nearly 30 times and only modest earnings growth expectations could be a drag for share price in 2022, as investors look for better deals in value and cyclical stocks.The Apple Maven’s takeI continue to think that Apple is a great stock to buy and hold for the long term. Under the leadership of a CEO (and former COO) that is driven by operational excellence, the company seems to be in very good hands. Better yet, demand for Apple’s products and services, as well as consumer appreciation for the brand, seem to be at or near an all-time high.That said, the setup for the first few weeks or months of 2022 looks challenging to me. Apple stock climbed relentlessly in 2020, and then again last year. Aided by a spike in pandemic-driven demand for tech devices and lavish liquidity in the system, AAPL recorded one of its best three years of returns ever between 2019 and 2021.As much as the metaverse and autonomous vehicles can and likely will support the company’s financial results over the next many years, I think that AAPL stock is overdue for a breather. While shares will likely climb back above $3 trillion and head much higher from there eventually, I am not so confident that this rally will happen in the immediate future.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":3585,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694538944,"gmtCreate":1642040417381,"gmtModify":1642040418204,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"&nbsp;Like","listText":"&nbsp;Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/694538944","repostId":"1138592368","repostType":4,"repost":{"id":"1138592368","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1641997842,"share":"https://www.laohunote.com/m/news/1138592368?lang=zh_CN&edition=full","pubTime":"2022-01-12 22:30","market":"us","language":"en","title":"Stocks rise as Wall Street shakes off red hot inflation report<blockquote>华尔街摆脱炙手可热的通胀报告，股市上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1138592368","media":"Tiger Newspress","summary":"Stocks rose Wednesday as investors eyed a new report on inflation, which showed another decades-high","content":"<p><html><head></head><body>Stocks rose Wednesday as investors eyed a new report on inflation, which showed another decades-high rate of price increases across the recovering economy. Still, this came a day following remarks from Federal Reserve Chair Jerome Powell reasserting that the central bank would step in as needed to rein in rising prices.</p><p><blockquote><html><head></head><body>周三股市上涨，投资者关注一份新的通胀报告，该报告显示，在复苏的经济中，物价涨幅再创数十年来新高。尽管如此，就在一天前，美联储主席杰罗姆·鲍威尔发表讲话，重申央行将根据需要进行干预，以控制物价上涨。</body></html></blockquote></p><p>The Bureau of Labor Statistics&#39; December Consumer Price Index (CPI)showed prices rose at a 7.0% year-over-year rate at the end of 2021, marking the fastest increase since 1982. This matched consensus estimates, based on Bloomberg data, and accelerated from November&#39;s already elevated 6.8% increase. On a month-over-month basis, consumer prices rose 0.5%, or slightly more than the 0.4% rise expected, to mark an eighteenth consecutive month of prices increases.</p><p><blockquote>美国劳工统计局12月消费者价格指数（CPI）显示，2021年底物价同比上涨7.0%，创下1982年以来最快涨幅。这与基于彭博社数据的普遍预期相符，并且比 11 月份已经高出的 6.8% 的增幅有所加快。按月计算，消费者价格上涨0.5%，略高于预期的0.4%，标志着价格连续第18个月上涨。</blockquote></p><p>Excluding food and energy prices, the so-called core measure of consumer prices rose 5.5% in December over last year, coming in at the fastest rate since 1991.</p><p><blockquote>剔除食品和能源价格，所谓的消费者价格核心指标 12 月份比去年上涨了 5.5%，创下 1991 年以来的最快增速。</blockquote></p><p>Wednesday&#39;s market moves came following a rebound rally on Tuesday, with markets at least temporarily finding relief in assurances from Federal Reserve Chair Jerome Powell that the central bank would step in as necessary to ease rising prices. InPowell&#39;s renomination hearing before the Senate Banking Committee, the central bank leader reiterated that the Fed would use its policy tools to bring down inflation.</p><p><blockquote>周三的市场走势是在周二反弹之后出现的，美联储主席杰罗姆·鲍威尔保证央行将在必要时介入以缓解物价上涨，这至少暂时缓解了市场的压力。在参议院银行委员会举行的鲍威尔连任听证会上，这位央行领导人重申，美联储将使用其政策工具来降低通胀。</blockquote></p><p>“If we see inflation persisting at high levels, longer than expected, if we have to raise interest rates more over time, then we will,” Powell said during the hearing.</p><p><blockquote>“鲍威尔在听证会上说：”如果我们看到通胀持续在高水平，比预期的要长，如果我们不得不随着时间的推移进一步加息，那么我们就会加息。</blockquote></p><p>The central bankpreviously telegraphed it was eyeing three interest rate hikesthis year to bring benchmark rates up from their current near-zero levels. However, some topWall Street firms have predictedthe Fed will raise rates four times given the current inflationary backdrop.</p><p><blockquote>央行此前曾表示，计划今年三次加息，将基准利率从目前接近于零的水平上调。然而，一些顶级华尔街公司预测，鉴于当前的通胀背景，美联储将加息四次。</blockquote></p><p>But though Powell doubled down on the Fed&#39;s goal of curbing inflation and using interest rate hikes as a tool to achieve this, he revealed little further about the Fed&#39;s plan to begin shrinking its nearly $9 trillion balance sheet. The Fed&#39;s December meeting minutes last week suggested central bank officials were beginning to discuss drawing down the Fed&#39;s balance sheet after nearly two years of asset purchases to help support markets during the pandemic. Powell did reiterate in his hearing he expected the balance sheet runoff process would begin this year.</p><p><blockquote>尽管鲍威尔加倍实现了美联储抑制通胀的目标，并将加息作为实现这一目标的工具，但他几乎没有透露美联储开始缩减近9万亿美元资产负债表的计划。美联储上周公布的 12 月会议纪要显示，央行官员开始讨论缩减美联储的资产负债表，此前他们购买了近两年的资产，以帮助在疫情期间支撑市场。鲍威尔在听证会上重申，他预计资产负债表决算程序将于今年开始。</blockquote></p><p>&#34;I think the biggest comment on most investors&#39; minds that we talk to around the world would be a &#39;policy mistake&#39; that the Fed might be too aggressive,&#34; Brian Belski, BMO Capital Markets chief investment strategist,told Yahoo Finance Live on Tuesday.&#34;Mr. Powell basically came out today and said this is going to be a process ... with respect to how long this is going to take, and I think that&#39;s what&#39;s calming investors.&#34;</p><p><blockquote>蒙特利尔银行资本市场首席投资策略师布莱恩·贝尔斯基 (Brian Belski) 周二对雅虎财经直播表示：“我认为，我们在世界各地与大多数投资者交谈时，对他们心目中最大的评论将是美联储可能过于激进的‘政策错误’。”鲍威尔今天基本上出来了，说这将是一个过程……至于这需要多长时间，我认为这就是让投资者平静下来的原因。”</blockquote></p><p>Though prospects of higher borrowing costs and tighter financial conditions have stirred up volatility in U.S. equities and tech stocks especially in recent sessions, Tuesday&#39;s session saw a reversal, with the tech-heavy Nasdaq Composite sharply outperforming.</p><p><blockquote>尽管借贷成本上升和金融状况收紧的前景引发了美国股市和科技股的波动，尤其是在最近几个交易日，但周二的交易日出现了逆转，以科技股为主的纳斯达克综合指数大幅跑赢大盘。</blockquote></p><p>&#34;The issue with tech, I would argue, is not so much one of a little extra duration exposure because growth is further away, but it&#39;s simply one of valuation,&#34; Simeon Hyman, ProShares Global Investment Strategist,told Yahoo Finance Live on Tuesday.&#34;And indeed those top-heavy, largest-cap tech stocks perhaps just were a little bit expensive going into the end of last year and the beginning of 2022. But don&#39;t completely rule out good growth stories because that is the biggest defense against inflation. It is the growth of earnings and dividends.&#34;</p><p><blockquote>ProShares 全球投资策略师西蒙·海曼 (Simeon Hyman) 周二对雅虎财经直播表示：“我认为，科技股的问题与其说是因为增长还很遥远，不如说是估值问题。”事实上，那些顶级重量级、市值最大的科技股在去年年底和 2022 年初可能有点贵。但不要完全排除良好的增长故事，因为这是对抗通货膨胀的最大防御。这是盈利和股息的增长。”</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks rise as Wall Street shakes off red hot inflation report<blockquote>华尔街摆脱炙手可热的通胀报告，股市上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks rise as Wall Street shakes off red hot inflation report<blockquote>华尔街摆脱炙手可热的通胀报告，股市上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2022-01-12 22:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>Stocks rose Wednesday as investors eyed a new report on inflation, which showed another decades-high rate of price increases across the recovering economy. Still, this came a day following remarks from Federal Reserve Chair Jerome Powell reasserting that the central bank would step in as needed to rein in rising prices.</p><p><blockquote><html><head></head><body>周三股市上涨，投资者关注一份新的通胀报告，该报告显示，在复苏的经济中，物价涨幅再创数十年来新高。尽管如此，就在一天前，美联储主席杰罗姆·鲍威尔发表讲话，重申央行将根据需要进行干预，以控制物价上涨。</body></html></blockquote></p><p>The Bureau of Labor Statistics&#39; December Consumer Price Index (CPI)showed prices rose at a 7.0% year-over-year rate at the end of 2021, marking the fastest increase since 1982. This matched consensus estimates, based on Bloomberg data, and accelerated from November&#39;s already elevated 6.8% increase. On a month-over-month basis, consumer prices rose 0.5%, or slightly more than the 0.4% rise expected, to mark an eighteenth consecutive month of prices increases.</p><p><blockquote>美国劳工统计局12月消费者价格指数（CPI）显示，2021年底物价同比上涨7.0%，创下1982年以来最快涨幅。这与基于彭博社数据的普遍预期相符，并且比 11 月份已经高出的 6.8% 的增幅有所加快。按月计算，消费者价格上涨0.5%，略高于预期的0.4%，标志着价格连续第18个月上涨。</blockquote></p><p>Excluding food and energy prices, the so-called core measure of consumer prices rose 5.5% in December over last year, coming in at the fastest rate since 1991.</p><p><blockquote>剔除食品和能源价格，所谓的消费者价格核心指标 12 月份比去年上涨了 5.5%，创下 1991 年以来的最快增速。</blockquote></p><p>Wednesday&#39;s market moves came following a rebound rally on Tuesday, with markets at least temporarily finding relief in assurances from Federal Reserve Chair Jerome Powell that the central bank would step in as necessary to ease rising prices. InPowell&#39;s renomination hearing before the Senate Banking Committee, the central bank leader reiterated that the Fed would use its policy tools to bring down inflation.</p><p><blockquote>周三的市场走势是在周二反弹之后出现的，美联储主席杰罗姆·鲍威尔保证央行将在必要时介入以缓解物价上涨，这至少暂时缓解了市场的压力。在参议院银行委员会举行的鲍威尔连任听证会上，这位央行领导人重申，美联储将使用其政策工具来降低通胀。</blockquote></p><p>“If we see inflation persisting at high levels, longer than expected, if we have to raise interest rates more over time, then we will,” Powell said during the hearing.</p><p><blockquote>“鲍威尔在听证会上说：”如果我们看到通胀持续在高水平，比预期的要长，如果我们不得不随着时间的推移进一步加息，那么我们就会加息。</blockquote></p><p>The central bankpreviously telegraphed it was eyeing three interest rate hikesthis year to bring benchmark rates up from their current near-zero levels. However, some topWall Street firms have predictedthe Fed will raise rates four times given the current inflationary backdrop.</p><p><blockquote>央行此前曾表示，计划今年三次加息，将基准利率从目前接近于零的水平上调。然而，一些顶级华尔街公司预测，鉴于当前的通胀背景，美联储将加息四次。</blockquote></p><p>But though Powell doubled down on the Fed&#39;s goal of curbing inflation and using interest rate hikes as a tool to achieve this, he revealed little further about the Fed&#39;s plan to begin shrinking its nearly $9 trillion balance sheet. The Fed&#39;s December meeting minutes last week suggested central bank officials were beginning to discuss drawing down the Fed&#39;s balance sheet after nearly two years of asset purchases to help support markets during the pandemic. Powell did reiterate in his hearing he expected the balance sheet runoff process would begin this year.</p><p><blockquote>尽管鲍威尔加倍实现了美联储抑制通胀的目标，并将加息作为实现这一目标的工具，但他几乎没有透露美联储开始缩减近9万亿美元资产负债表的计划。美联储上周公布的 12 月会议纪要显示，央行官员开始讨论缩减美联储的资产负债表，此前他们购买了近两年的资产，以帮助在疫情期间支撑市场。鲍威尔在听证会上重申，他预计资产负债表决算程序将于今年开始。</blockquote></p><p>&#34;I think the biggest comment on most investors&#39; minds that we talk to around the world would be a &#39;policy mistake&#39; that the Fed might be too aggressive,&#34; Brian Belski, BMO Capital Markets chief investment strategist,told Yahoo Finance Live on Tuesday.&#34;Mr. Powell basically came out today and said this is going to be a process ... with respect to how long this is going to take, and I think that&#39;s what&#39;s calming investors.&#34;</p><p><blockquote>蒙特利尔银行资本市场首席投资策略师布莱恩·贝尔斯基 (Brian Belski) 周二对雅虎财经直播表示：“我认为，我们在世界各地与大多数投资者交谈时，对他们心目中最大的评论将是美联储可能过于激进的‘政策错误’。”鲍威尔今天基本上出来了，说这将是一个过程……至于这需要多长时间，我认为这就是让投资者平静下来的原因。”</blockquote></p><p>Though prospects of higher borrowing costs and tighter financial conditions have stirred up volatility in U.S. equities and tech stocks especially in recent sessions, Tuesday&#39;s session saw a reversal, with the tech-heavy Nasdaq Composite sharply outperforming.</p><p><blockquote>尽管借贷成本上升和金融状况收紧的前景引发了美国股市和科技股的波动，尤其是在最近几个交易日，但周二的交易日出现了逆转，以科技股为主的纳斯达克综合指数大幅跑赢大盘。</blockquote></p><p>&#34;The issue with tech, I would argue, is not so much one of a little extra duration exposure because growth is further away, but it&#39;s simply one of valuation,&#34; Simeon Hyman, ProShares Global Investment Strategist,told Yahoo Finance Live on Tuesday.&#34;And indeed those top-heavy, largest-cap tech stocks perhaps just were a little bit expensive going into the end of last year and the beginning of 2022. But don&#39;t completely rule out good growth stories because that is the biggest defense against inflation. It is the growth of earnings and dividends.&#34;</p><p><blockquote>ProShares 全球投资策略师西蒙·海曼 (Simeon Hyman) 周二对雅虎财经直播表示：“我认为，科技股的问题与其说是因为增长还很遥远，不如说是估值问题。”事实上，那些顶级重量级、市值最大的科技股在去年年底和 2022 年初可能有点贵。但不要完全排除良好的增长故事，因为这是对抗通货膨胀的最大防御。这是盈利和股息的增长。”</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138592368","content_text":"Stocks rose Wednesday as investors eyed a new report on inflation, which showed another decades-high rate of price increases across the recovering economy. Still, this came a day following remarks from Federal Reserve Chair Jerome Powell reasserting that the central bank would step in as needed to rein in rising prices.The Bureau of Labor Statistics' December Consumer Price Index (CPI)showed prices rose at a 7.0% year-over-year rate at the end of 2021, marking the fastest increase since 1982. This matched consensus estimates, based on Bloomberg data, and accelerated from November's already elevated 6.8% increase. On a month-over-month basis, consumer prices rose 0.5%, or slightly more than the 0.4% rise expected, to mark an eighteenth consecutive month of prices increases.Excluding food and energy prices, the so-called core measure of consumer prices rose 5.5% in December over last year, coming in at the fastest rate since 1991.Wednesday's market moves came following a rebound rally on Tuesday, with markets at least temporarily finding relief in assurances from Federal Reserve Chair Jerome Powell that the central bank would step in as necessary to ease rising prices. InPowell's renomination hearing before the Senate Banking Committee, the central bank leader reiterated that the Fed would use its policy tools to bring down inflation.“If we see inflation persisting at high levels, longer than expected, if we have to raise interest rates more over time, then we will,” Powell said during the hearing.The central bankpreviously telegraphed it was eyeing three interest rate hikesthis year to bring benchmark rates up from their current near-zero levels. However, some topWall Street firms have predictedthe Fed will raise rates four times given the current inflationary backdrop.But though Powell doubled down on the Fed's goal of curbing inflation and using interest rate hikes as a tool to achieve this, he revealed little further about the Fed's plan to begin shrinking its nearly $9 trillion balance sheet. The Fed's December meeting minutes last week suggested central bank officials were beginning to discuss drawing down the Fed's balance sheet after nearly two years of asset purchases to help support markets during the pandemic. Powell did reiterate in his hearing he expected the balance sheet runoff process would begin this year.\"I think the biggest comment on most investors' minds that we talk to around the world would be a 'policy mistake' that the Fed might be too aggressive,\" Brian Belski, BMO Capital Markets chief investment strategist,told Yahoo Finance Live on Tuesday.\"Mr. Powell basically came out today and said this is going to be a process ... with respect to how long this is going to take, and I think that's what's calming investors.\"Though prospects of higher borrowing costs and tighter financial conditions have stirred up volatility in U.S. equities and tech stocks especially in recent sessions, Tuesday's session saw a reversal, with the tech-heavy Nasdaq Composite sharply outperforming.\"The issue with tech, I would argue, is not so much one of a little extra duration exposure because growth is further away, but it's simply one of valuation,\" Simeon Hyman, ProShares Global Investment Strategist,told Yahoo Finance Live on Tuesday.\"And indeed those top-heavy, largest-cap tech stocks perhaps just were a little bit expensive going into the end of last year and the beginning of 2022. But don't completely rule out good growth stories because that is the biggest defense against inflation. It is the growth of earnings and dividends.\"","news_type":1,"symbols_score_info":{".SPX":0.9,".DJI":0.9,".IXIC":0.9}},"isVote":1,"tweetType":1,"viewCount":4789,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694607018,"gmtCreate":1641944862640,"gmtModify":1641944863458,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Good and like&nbsp;","listText":"Good and like&nbsp;","text":"Good and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/694607018","repostId":"2201214004","repostType":4,"isVote":1,"tweetType":1,"viewCount":2142,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694604427,"gmtCreate":1641944810065,"gmtModify":1641944810871,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/694604427","repostId":"1134509683","repostType":4,"repost":{"id":"1134509683","kind":"news","pubTimestamp":1641612579,"share":"https://www.laohunote.com/m/news/1134509683?lang=zh_CN&edition=full","pubTime":"2022-01-08 11:29","market":"us","language":"en","title":"3 COVID Stocks That Will Make Billions in 2022<blockquote>2022 年将赚取数十亿美元的 3 只新冠股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1134509683","media":"Motley Fool","summary":"These three COVID-19 stocks could rake in a tremendous amount of cash this year.","content":"<p><html><head></head><body>It&#39;s a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.</p><p><blockquote><html><head></head><body>新的一年了，新冠肺炎仍然和我们在一起。去年，我们看到了医疗保健领域多种COVID疫苗和治疗的紧急使用授权。制药公司将在 2022 年赚取数十亿美元。以下是三只应该蓬勃发展的股票。</body></html></blockquote></p><p><b>Pfizer</b>(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy <b>Novavax</b>(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in <b>Vir Biotechnology</b>(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.</p><p><blockquote><b>辉瑞</b>（纽约证券交易所股票代码：PFE）是一家价值 3100 亿美元的巨型公司，预计其新冠疫苗和抗病毒药丸的销售额将不是 10 亿美元或 100 亿美元，而是超过 500 亿美元。好斗<b>诺瓦瓦克斯</b>（纳斯达克股票代码：NVAX）终于在世界各地推出了新冠疫苗。它将获得多少亿？我们有一个黑马候选人<b>生物技术</b>（纳斯达克股票代码：VIR）它有一种药物很容易成为小型生物技术公司10亿美元的重磅炸弹。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/488a166201699c1f3d6536aa3e640ecf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p><b>A safe harbor in stormy weather</b></p><p><blockquote><b>暴风雨天气中的安全港湾</b></blockquote></p><p><b>George Budwell(Pfizer):</b>Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.</p><p><blockquote><b>乔治·布德威尔（辉瑞）：</b>辉瑞是新冠肺炎药品无可争议的冠军。仅在 2022 年，华尔街预计这家制药巨头的新型冠状病毒疫苗 Comirnaty 和口服抗病毒药 Paxlovid 的销售额将达到 550 亿美元。</blockquote></p><p>What&#39;s more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.</p><p><blockquote>更重要的是，分析师开始接受 Paxlovid 可能成为该公司当前十年可持续收入来源的想法。上个月，当美国食品药品监督管理局根据紧急使用授权途径首次允许该药物投放市场时，华尔街认为 Paxlovid 可能会在一年左右的时间内达到商业顶峰，然后随着疫情淡出视野，销售额将大幅下降。</blockquote></p><p>But less than three weeks out from the drug&#39;s initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.</p><p><blockquote>但距离该药物首次批准还有不到三周的时间，很明显，Paxlovid 可能会在未来几年内被用作防止 COVID-19 最糟糕后果的故障安全药物。毕竟，高度传染性的奥密克戎变种肯定不会是该病毒的最后一次重大迭代。</blockquote></p><p>What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.</p><p><blockquote>这一切意味着辉瑞应该是少数几家拥有可观的长期 COVID-19 收入来源的大型制药商之一。反过来，辉瑞应该有充足的自由现金流来满足其慷慨的股东奖励计划以及在可预见的未来雄心勃勃的业务发展计划。</blockquote></p><p>So, if you&#39;re looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.</p><p><blockquote>因此，如果您正在寻找一只能够经受住高通胀和利率上升双重阻力的股票，辉瑞可能值得一看。</blockquote></p><p><b>Revenue forecasts for Novavax:  $2 billion to $8 billion</b></p><p><blockquote><b>Novavax 收入预测：20 亿至 80 亿美元</b></blockquote></p><p><b>Taylor Carmichael(Novavax):</b>Novavax is on the verge of greatness this year. The company&#39;s stock price is down to $125 a share. That&#39;s where it started in 2021, so last year was pretty much a washout for the stock.</p><p><blockquote><b>泰勒·卡迈克尔（诺瓦瓦克斯）：</b>Novavax 今年正处于伟大的边缘。该公司股价跌至每股 125 美元。这就是它在 2021 年开始的地方，所以去年对于该股来说几乎是一次洗牌。</blockquote></p><p>Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.</p><p><blockquote>早在 2 月份，当 Novavax 报告其 COVID 疫苗的 3 期数据积极时，股价就飙升至 300 美元以上。但后来这家小型生物技术公司遇到了制造问题。虽然许多人称其疫苗是同类产品中最好的，但扩大约 20 亿剂疫苗的合同生产规模说起来容易做起来难。这些现实导致该股从高点下跌了约 60%。</blockquote></p><p>Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it&#39;s highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company&#39;s already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.</p><p><blockquote>尽管如此，Novavax 的收入已经达到了 10 亿美元大关，因此由于所有的预购，其疫苗甚至在获得批准之前就已经大受欢迎。现在，来自全球各地的授权纷至沓来，Novavax很有可能在2022年运送大量疫苗剂量。该公司已经实现了每月1亿剂的生产能力，即一年12亿剂。在第三季度财报看涨期权上，管理层预测到第四季度末将达到每月1.5亿剂（或每年18亿剂）的产能。该公司预计将继续扩大规模，并预测 2022 年将分发 20 亿剂疫苗。</blockquote></p><p>Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that&#39;s over $4 billion in sales, just in Europe.</p><p><blockquote>20亿剂疫苗，价格为16美元（曲速行动支付了16亿美元预购1亿剂），我们得到了320亿美元的收入。当然，Novavax将以较低的速度向发展中国家分发大量疫苗。虽然该公司对其价格保持沉默，但丹麦早在 8 月份就表示，根据欧盟 (EU) 协议，它每剂支付了近 21 美元。欧盟已经订购了2亿剂，仅在欧洲的销售额就超过了40亿美元。</blockquote></p><p></p><p>Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company&#39;s market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.</p><p><blockquote>分析师极其保守，预测 Novavax 2022 年的市值在 20 亿至 80 亿美元之间。（该公司的市值为 90 亿美元。）虽然一路上可能会出现一些小问题，但 Novavax 肯定会在 2022 年从其 COVID-19 疫苗中赚取数十亿美元。如果该公司确实像所说的那样交付了 20 亿剂疫苗，那么该股可能会有显着的上涨空间。</blockquote></p><p><b>The antibody market all to itself</b></p><p><blockquote><b>抗体市场本身</b></blockquote></p><p><b>Patrick Bafuma(Vir Biotechnology):</b>The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from <b>Eli Lilly</b> (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from <b>Roche</b>and<b>Regeneron</b> are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--<b>GlaxoSmithKline</b> and Vir Biotechnology&#39;s sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it&#39;s the only one left right now to fight the omicron variant.</p><p><blockquote><b>Patrick Bafuma（来自生物技术）：</b>奥密克戎变种目前正在猖獗，这一次，我们缺少一些治疗方法。以前青睐的单克隆抗体治疗来自<b>礼来</b>（bamlanivimab加etesevimab）以及来自<b>罗氏</b>和<b>再生元</b>被认为对当前变体的活性明显减弱。这样就只剩下一个能有效对抗奥密克戎--<b>葛兰素史克</b>以及 Vir Biotechnology 的 sotrovimab。这种单克隆抗体此前已证明，患有轻度至中度 COVID-19 且有发展为严重疾病高风险的成年人的住院和死亡风险降低了 79%。这是现在唯一一个对抗奥密克戎变种的人。</blockquote></p><p>Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly&#39;s antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.</p><p><blockquote>作为该区块上唯一的单克隆抗体将有其特权。2021 年前 9 个月，REGEN-COV 带来了 35 亿美元的产品净销售额，而礼来公司的抗体组合带来了 11.7 亿美元的收入。美国政府已经签订了价值约10亿美元的sotrovimab合同。随着医院里挤满了病人，任何有助于减轻系统压力的东西都可能会受到高度追捧。</blockquote></p><p>And while Pfizer&#39;s Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who&#39;s who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid&#39;s possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.</p><p><blockquote>虽然辉瑞的 Paxlovid 将极大地有助于减轻 COVID-19 对医疗保健系统的负担，但口服药物具有显着且复杂的药物相互作用潜力。事实上，它的相互作用列表读起来就像常用处方药物的名人录。这包括流行的血液稀释剂，如波立维和Xarelto，常见的镇痛药，如曲马多和羟考酮，抗焦虑药，如Klonopin和Xanax，以及抗胆固醇他汀类药物。随着美国国立卫生研究院发表声明，对Paxlovid可能的药物相互作用表示担忧，这为sotrovimab继续广泛使用留下了足够的空间。根据与葛兰素史克的协议，Vir 获得了 sotrovimab 72.5% 的销售额，这家价值 44 亿美元的生物技术公司目前看起来很划算。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 COVID Stocks That Will Make Billions in 2022<blockquote>2022 年将赚取数十亿美元的 3 只新冠股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 COVID Stocks That Will Make Billions in 2022<blockquote>2022 年将赚取数十亿美元的 3 只新冠股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2022-01-08 11:29</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>It&#39;s a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.</p><p><blockquote><html><head></head><body>新的一年了，新冠肺炎仍然和我们在一起。去年，我们看到了医疗保健领域多种COVID疫苗和治疗的紧急使用授权。制药公司将在 2022 年赚取数十亿美元。以下是三只应该蓬勃发展的股票。</body></html></blockquote></p><p><b>Pfizer</b>(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy <b>Novavax</b>(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in <b>Vir Biotechnology</b>(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.</p><p><blockquote><b>辉瑞</b>（纽约证券交易所股票代码：PFE）是一家价值 3100 亿美元的巨型公司，预计其新冠疫苗和抗病毒药丸的销售额将不是 10 亿美元或 100 亿美元，而是超过 500 亿美元。好斗<b>诺瓦瓦克斯</b>（纳斯达克股票代码：NVAX）终于在世界各地推出了新冠疫苗。它将获得多少亿？我们有一个黑马候选人<b>生物技术</b>（纳斯达克股票代码：VIR）它有一种药物很容易成为小型生物技术公司10亿美元的重磅炸弹。</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/488a166201699c1f3d6536aa3e640ecf\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"/><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p><b>A safe harbor in stormy weather</b></p><p><blockquote><b>暴风雨天气中的安全港湾</b></blockquote></p><p><b>George Budwell(Pfizer):</b>Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.</p><p><blockquote><b>乔治·布德威尔（辉瑞）：</b>辉瑞是新冠肺炎药品无可争议的冠军。仅在 2022 年，华尔街预计这家制药巨头的新型冠状病毒疫苗 Comirnaty 和口服抗病毒药 Paxlovid 的销售额将达到 550 亿美元。</blockquote></p><p>What&#39;s more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.</p><p><blockquote>更重要的是，分析师开始接受 Paxlovid 可能成为该公司当前十年可持续收入来源的想法。上个月，当美国食品药品监督管理局根据紧急使用授权途径首次允许该药物投放市场时，华尔街认为 Paxlovid 可能会在一年左右的时间内达到商业顶峰，然后随着疫情淡出视野，销售额将大幅下降。</blockquote></p><p>But less than three weeks out from the drug&#39;s initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.</p><p><blockquote>但距离该药物首次批准还有不到三周的时间，很明显，Paxlovid 可能会在未来几年内被用作防止 COVID-19 最糟糕后果的故障安全药物。毕竟，高度传染性的奥密克戎变种肯定不会是该病毒的最后一次重大迭代。</blockquote></p><p>What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.</p><p><blockquote>这一切意味着辉瑞应该是少数几家拥有可观的长期 COVID-19 收入来源的大型制药商之一。反过来，辉瑞应该有充足的自由现金流来满足其慷慨的股东奖励计划以及在可预见的未来雄心勃勃的业务发展计划。</blockquote></p><p>So, if you&#39;re looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.</p><p><blockquote>因此，如果您正在寻找一只能够经受住高通胀和利率上升双重阻力的股票，辉瑞可能值得一看。</blockquote></p><p><b>Revenue forecasts for Novavax:  $2 billion to $8 billion</b></p><p><blockquote><b>Novavax 收入预测：20 亿至 80 亿美元</b></blockquote></p><p><b>Taylor Carmichael(Novavax):</b>Novavax is on the verge of greatness this year. The company&#39;s stock price is down to $125 a share. That&#39;s where it started in 2021, so last year was pretty much a washout for the stock.</p><p><blockquote><b>泰勒·卡迈克尔（诺瓦瓦克斯）：</b>Novavax 今年正处于伟大的边缘。该公司股价跌至每股 125 美元。这就是它在 2021 年开始的地方，所以去年对于该股来说几乎是一次洗牌。</blockquote></p><p>Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.</p><p><blockquote>早在 2 月份，当 Novavax 报告其 COVID 疫苗的 3 期数据积极时，股价就飙升至 300 美元以上。但后来这家小型生物技术公司遇到了制造问题。虽然许多人称其疫苗是同类产品中最好的，但扩大约 20 亿剂疫苗的合同生产规模说起来容易做起来难。这些现实导致该股从高点下跌了约 60%。</blockquote></p><p>Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it&#39;s highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company&#39;s already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.</p><p><blockquote>尽管如此，Novavax 的收入已经达到了 10 亿美元大关，因此由于所有的预购，其疫苗甚至在获得批准之前就已经大受欢迎。现在，来自全球各地的授权纷至沓来，Novavax很有可能在2022年运送大量疫苗剂量。该公司已经实现了每月1亿剂的生产能力，即一年12亿剂。在第三季度财报看涨期权上，管理层预测到第四季度末将达到每月1.5亿剂（或每年18亿剂）的产能。该公司预计将继续扩大规模，并预测 2022 年将分发 20 亿剂疫苗。</blockquote></p><p>Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that&#39;s over $4 billion in sales, just in Europe.</p><p><blockquote>20亿剂疫苗，价格为16美元（曲速行动支付了16亿美元预购1亿剂），我们得到了320亿美元的收入。当然，Novavax将以较低的速度向发展中国家分发大量疫苗。虽然该公司对其价格保持沉默，但丹麦早在 8 月份就表示，根据欧盟 (EU) 协议，它每剂支付了近 21 美元。欧盟已经订购了2亿剂，仅在欧洲的销售额就超过了40亿美元。</blockquote></p><p></p><p>Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company&#39;s market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.</p><p><blockquote>分析师极其保守，预测 Novavax 2022 年的市值在 20 亿至 80 亿美元之间。（该公司的市值为 90 亿美元。）虽然一路上可能会出现一些小问题，但 Novavax 肯定会在 2022 年从其 COVID-19 疫苗中赚取数十亿美元。如果该公司确实像所说的那样交付了 20 亿剂疫苗，那么该股可能会有显着的上涨空间。</blockquote></p><p><b>The antibody market all to itself</b></p><p><blockquote><b>抗体市场本身</b></blockquote></p><p><b>Patrick Bafuma(Vir Biotechnology):</b>The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from <b>Eli Lilly</b> (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from <b>Roche</b>and<b>Regeneron</b> are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--<b>GlaxoSmithKline</b> and Vir Biotechnology&#39;s sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it&#39;s the only one left right now to fight the omicron variant.</p><p><blockquote><b>Patrick Bafuma（来自生物技术）：</b>奥密克戎变种目前正在猖獗，这一次，我们缺少一些治疗方法。以前青睐的单克隆抗体治疗来自<b>礼来</b>（bamlanivimab加etesevimab）以及来自<b>罗氏</b>和<b>再生元</b>被认为对当前变体的活性明显减弱。这样就只剩下一个能有效对抗奥密克戎--<b>葛兰素史克</b>以及 Vir Biotechnology 的 sotrovimab。这种单克隆抗体此前已证明，患有轻度至中度 COVID-19 且有发展为严重疾病高风险的成年人的住院和死亡风险降低了 79%。这是现在唯一一个对抗奥密克戎变种的人。</blockquote></p><p>Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly&#39;s antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.</p><p><blockquote>作为该区块上唯一的单克隆抗体将有其特权。2021 年前 9 个月，REGEN-COV 带来了 35 亿美元的产品净销售额，而礼来公司的抗体组合带来了 11.7 亿美元的收入。美国政府已经签订了价值约10亿美元的sotrovimab合同。随着医院里挤满了病人，任何有助于减轻系统压力的东西都可能会受到高度追捧。</blockquote></p><p>And while Pfizer&#39;s Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who&#39;s who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid&#39;s possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.</p><p><blockquote>虽然辉瑞的 Paxlovid 将极大地有助于减轻 COVID-19 对医疗保健系统的负担，但口服药物具有显着且复杂的药物相互作用潜力。事实上，它的相互作用列表读起来就像常用处方药物的名人录。这包括流行的血液稀释剂，如波立维和Xarelto，常见的镇痛药，如曲马多和羟考酮，抗焦虑药，如Klonopin和Xanax，以及抗胆固醇他汀类药物。随着美国国立卫生研究院发表声明，对Paxlovid可能的药物相互作用表示担忧，这为sotrovimab继续广泛使用留下了足够的空间。根据与葛兰素史克的协议，Vir 获得了 sotrovimab 72.5% 的销售额，这家价值 44 亿美元的生物技术公司目前看起来很划算。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","VIR":"Vir Biotechnology, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2022/01/07/3-covid-stocks-that-will-make-billions-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134509683","content_text":"It's a new year and COVID-19 is still with us. Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Here are three stocks that should thrive.Pfizer(NYSE:PFE), the $310 billion mega cap, is expected to bring in not $1 billion or $10 billion but over $50 billion in sales for its COVID vaccine and antiviral pill. Scrappy Novavax(NASDAQ:NVAX)is finally introducing its COVID vaccine around the world. How many billions will it receive? And we have a dark horse candidate in Vir Biotechnology(NASDAQ:VIR). It has a drug that could easily be a $1 billion blockbuster for the tiny biotech.IMAGE SOURCE: GETTY IMAGES.A safe harbor in stormy weatherGeorge Budwell(Pfizer):Pfizer is the undisputed champion of COVID-19 pharmaceutical products. In 2022 alone, Wall Street expects the pharma giant to rake in $55 billion in sales between its novel coronavirus vaccine, Comirnaty, and its oral antiviral pill, Paxlovid.What's more, analysts are starting to warm up to the idea that Paxlovid might be a sustainable revenue generator for the company over the course of the current decade. When the drug was first allowed on the market by the Food and Drug Administration under the Emergency Use Authorization pathway last month, Wall Street thought Paxlovid would likely peak from a commercial standpoint within a year or so, and then experience a dramatic drop in sales as the pandemic faded from view.But less than three weeks out from the drug's initial approval, it is becoming painfully obvious that Paxlovid will probably be required as a fail-safe against the worst outcomes from COVID-19 for several more years. The highly infectious omicron variant, after all, will certainly not be the last major iteration of the virus.What this all means is that Pfizer ought to be one of the few large-cap drugmakers with a sizable, long-term COVID-19 revenue source. Pfizer, in turn, should have ample free cash flows to feed its generous shareholder reward program, as well as its ambitious business development plans, for the foreseeable future.So, if you're looking for a stock that can weather the dual headwinds of sky-high inflation and rising interest rates, Pfizer might be worth checking out.Revenue forecasts for Novavax:  $2 billion to $8 billionTaylor Carmichael(Novavax):Novavax is on the verge of greatness this year. The company's stock price is down to $125 a share. That's where it started in 2021, so last year was pretty much a washout for the stock.Back in February the share price zoomed over $300 when Novavax reported positive phase 3 data for its COVID vaccine. But then the small biotech ran into manufacturing issues. While its vaccine is said by many to be the best in class, scaling up the contract manufacturing for an estimated 2 billion doses of vaccine is easier said than done. And those realities have caused the stock to drop about 60% off its highs.Nonetheless, Novavax has already hit the $1 billion revenue mark, so its vaccine was a blockbuster even before it was approved, because of all the preorders. Now that authorizations are pouring in from around the globe, it's highly likely that Novavax will ship a massive number of vaccine doses in 2022. The company's already achieved a manufacturing capacity of 100 million doses a month, or 1.2 billion doses in a year. On the third-quarter earnings call, management predicted it would reach a manufacturing capacity of 150 million doses every month (or 1.8 billion doses a year) by the end of the fourth quarter. And the company expects to continue to scale and forecasts that it will distribute 2 billion doses in 2022.Two billion doses of vaccine, at a price point of $16 (Operation Warp Speed paid $1.6 billion to pre-order 100 million doses) gives us a back-of-the-envelope calculation of $32 billion in revenue. Of course, Novavax will be distributing a lot of vaccines to the developing world at a reduced rate. While the company has been quiet about its prices, Denmark said back in August that it paid almost $21 a dose under the European Union (EU) agreement. The EU has ordered 200 million doses, so that's over $4 billion in sales, just in Europe.Analysts are being extremely conservative, with a forecast ranging from $2 billion to $8 billion for Novavax in 2022. (The company's market cap sits at $9 billion.) While there may be hiccups along the way, Novavax is sure to make billions of dollars off its COVID-19 vaccine in 2022. And there could be significant upside to the stock if the company does indeed deliver 2 billion doses as it says it will.The antibody market all to itselfPatrick Bafuma(Vir Biotechnology):The omicron variant is currently running rampant, and this time, we are short a few treatments. Previously favored monoclonal antibody treatments from Eli Lilly (bamlanivimab plus etesevimab) as well as the REGEN-COV cocktail from RocheandRegeneron are believed to have marked diminished activity against the current variant. This leaves a single infusiont hought to be active against omicron--GlaxoSmithKline and Vir Biotechnology's sotrovimab. This monoclonal antibody previously demonstrated a reduced risk of hospitalization and death by 79% in adults with mild to moderate COVID-19 and at high risk of progression to severe disease. And it's the only one left right now to fight the omicron variant.Being the sole monoclonal antibody on the block will have its privileges. Through the first nine months of 2021, REGEN-COV brought in $3.5 billion in net product sales, while Eli Lilly's antibody combination brought in $1.17 billion. The U.S. government has already contracted for approximately $1 billion worth of sotrovimab. With hospitals overflowing with patients, anything that can help alleviate some of the stress on the system is likely going to be highly sought after.And while Pfizer's Paxlovid will be hugely beneficial to ease the COVID-19 burden on the healthcare system, the oral medication has significant and complex drug-drug interaction potential. In fact, its interaction list reads like a who's who of commonly prescribed medications. This includes popular blood thinning agents such as Plavix and Xarelto, common analgesics like Tramadol and oxycodone, anxiolytics like Klonopin and Xanax, as well as cholesterol-fighting statins. With the National Institutes of Health issuing a statement voicing its concern over Paxlovid's possible drug interactions, this leaves plenty of room for sotrovimab to continue to be widely prescribed. With Vir getting 72.5% of sotrovimab sales per its agreement with GSK, the $4.4 billion biotech looks like a bargain right now.","news_type":1,"symbols_score_info":{"NVAX":0.9,"PFE":0.9,"VIR":0.9}},"isVote":1,"tweetType":1,"viewCount":2993,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694604529,"gmtCreate":1641944786403,"gmtModify":1641944787198,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/694604529","repostId":"1198290127","repostType":4,"repost":{"id":"1198290127","kind":"news","pubTimestamp":1641702682,"share":"https://www.laohunote.com/m/news/1198290127?lang=zh_CN&edition=full","pubTime":"2022-01-09 12:31","market":"us","language":"en","title":"Can Apple Stock Reclaim $3 Trillion And Thrive In 2022?<blockquote>苹果股票能否在2022年收回3万亿美元并蓬勃发展？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1198290127","media":"TheStreet","summary":"A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready","content":"<p><html><head></head><body>A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready to break through yet. Can shares reclaim the milestone soon and head higher in 2022?</p><p><blockquote><html><head></head><body>到目前为止，3 万亿美元的市值已被证明是苹果股票似乎尚未准备好突破的上限。股价能否很快夺回里程碑并在 2022 年走高？</body></html></blockquote></p><p>Recently, Apple stock flirted with $3 trillion in market cap, but quickly dipped below $2.9 trillion — as the broad market reacted to monetary tightening that should now happen more rapidly than previously expected.</p><p><blockquote>最近，苹果股票的市值接近 3 万亿美元，但很快跌破 2.9 万亿美元——因为大盘对货币紧缩政策的反应应该比之前预期的更快。</blockquote></p><p>Can shares of the Cupertino company finally find its way north in 2022 and meet the expectations of so many bulls on Wall Street? Or will bearishness take over during a year of rising interest rates and lingering inflation?</p><p><blockquote>这家库比蒂诺公司的股票最终能否在 2022 年找到北上之路，并满足华尔街众多多头的期望？或者，在利率上升和通胀挥之不去的一年里，看跌情绪会接管吗？</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1f77cd919bf55f9c7b79f631b0255910\" tg-width=\"1240\" tg-height=\"697\" referrerpolicy=\"no-referrer\"/><span>Figure 1: Apple Park in Cupertino, CA.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：加利福尼亚州库比蒂诺的苹果公园。</span></p></blockquote></p><p><b>AAPL: the bull case</b></p><p><blockquote><b>AAPL：牛市案例</b></blockquote></p><p>As Apple stock climbed viciously between late November and early December, many Wall Street experts piled on in support of “AAPL $3T”. Wedbush’s Dan Ives, for example, has been talking about the market cap milestone since our conversation in Q3 of last year, at least.</p><p><blockquote>随着苹果股价在 11 月底至 12 月初疯狂攀升，许多华尔街专家纷纷支持 “AAPL 3 万亿美元 ”。例如，至少从我们去年第三季度的谈话开始，Wedbush 的丹-艾夫斯（Dan Ives）就一直在谈论市值里程碑。</blockquote></p><p>But other analysts have also hopped on the bullish bandwagon recently. Morgan Stanley upped its price target to $200 per share in November, while the JPMorgan research team saw Apple stock heading to $3.5 trillion in market cap over the next 12 months.</p><p><blockquote>但其他分析师最近也加入了看涨行列。摩根士丹利在 11 月份将目标价上调至每股 200 美元，而摩根大通研究团队则预计苹果股票在未来 12 个月内市值将达到 3.5 万亿美元。</blockquote></p><p>One of the most vocal optimists came from the buy side. Loup’s Gene Munster thought that his previous price target had quickly become stale, and that $250 per share now seemed more reasonable. In his opinion, the multi-year opportunity in the metaverse will gain investor appreciation in the new year, which should reignite momentum that the stock had lost in the last few weeks of 2021.</p><p><blockquote>最直言不讳的乐观主义者之一来自买方。Loup 的吉恩-明斯特（Gene Munster）认为，他之前的目标价很快就过时了，现在每股 250 美元似乎更合理。他认为，元宇宙的多年机会将在新的一年获得投资者的赞赏，这应该会重新点燃该股在2021年最后几周失去的势头。</blockquote></p><p><b>AAPL: the bear case</b></p><p><blockquote><b>AAPL：熊案</b></blockquote></p><p>Despite the upbeat expectations described above, mostly supported by company-specific factors, the market rolled into 2022 with its guard up. The boogieman of the moment seems to be the Federal Reserve’s anticipated reaction to near-full employment and sticky inflation, which should lead to higher interest rates in the next several months.</p><p><blockquote>尽管上述乐观预期主要受到公司特定因素的支持，但市场进入 2022 年仍保持警惕。目前的祸根似乎是美联储对接近充分就业和粘性通胀的预期反应，这将导致未来几个月利率上升。</blockquote></p><p>I have recently explained how tighter money supply can spell trouble for stocks that trade for relatively high multiples. While AAPL is no Tesla or Rivian, the stock’s forward P/E of nearly 30 times and only modest earnings growth expectations could be a drag for share price in 2022, as investors look for better deals in value and cyclical stocks.</p><p><blockquote>我最近解释了货币供应收紧如何给市盈率相对较高的股票带来麻烦。虽然 AAPL 不是特斯拉或Rivian，但该股近 30 倍的远期市盈率和温和的盈利增长预期可能会拖累 2022 年的股价，因为投资者正在寻找价值股和周期性股票的更好交易。</blockquote></p><p><b>The Apple Maven’s take</b></p><p><blockquote><b>苹果专家的看法</b></blockquote></p><p>I continue to think that Apple is a great stock to buy and hold for the long term. Under the leadership of a CEO (and former COO) that is driven by operational excellence, the company seems to be in very good hands. Better yet, demand for Apple’s products and services, as well as consumer appreciation for the brand, seem to be at or near an all-time high.</p><p><blockquote>我仍然认为苹果是一只值得长期购买和持有的好股票。在以卓越运营为动力的首席执行官（兼前首席运营官）的领导下，公司似乎得到了很好的管理。更好的是，对苹果产品和服务的需求以及消费者对该品牌的欣赏似乎处于或接近历史最高水平。</blockquote></p><p>That said, the setup for the first few weeks or months of 2022 looks challenging to me. Apple stock climbed relentlessly in 2020, and then again last year. Aided by a spike in pandemic-driven demand for tech devices and lavish liquidity in the system, AAPL recorded one of its best three years of returns ever between 2019 and 2021.</p><p><blockquote>也就是说，2022 年头几周或几个月的设置对我来说很有挑战性。苹果股价在 2020 年持续攀升，去年又再次攀升。得益于疫情推动的技术设备需求激增以及系统中充足的流动性，苹果公司在 2019 年至 2021 年间创下了有史以来最好的三年回报之一。</blockquote></p><p>As much as the metaverse and autonomous vehicles can and likely will support the company’s financial results over the next many years, I think that AAPL stock is overdue for a breather. While shares will likely climb back above $3 trillion and head much higher from there eventually, I am not so confident that this rally will happen in the immediate future.</p><p><blockquote>尽管元宇宙和自动驾驶汽车能够并可能在未来许多年为公司的财务业绩提供支持，但我认为苹果公司的股票早该喘口气了。虽然股价可能会回升至 3 万亿美元以上，并最终从那里走得更高，但我对这种反弹会在不久的将来发生并不那么有信心。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can Apple Stock Reclaim $3 Trillion And Thrive In 2022?<blockquote>苹果股票能否在2022年收回3万亿美元并蓬勃发展？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan Apple Stock Reclaim $3 Trillion And Thrive In 2022?<blockquote>苹果股票能否在2022年收回3万亿美元并蓬勃发展？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2022-01-09 12:31</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready to break through yet. Can shares reclaim the milestone soon and head higher in 2022?</p><p><blockquote><html><head></head><body>到目前为止，3 万亿美元的市值已被证明是苹果股票似乎尚未准备好突破的上限。股价能否很快夺回里程碑并在 2022 年走高？</body></html></blockquote></p><p>Recently, Apple stock flirted with $3 trillion in market cap, but quickly dipped below $2.9 trillion — as the broad market reacted to monetary tightening that should now happen more rapidly than previously expected.</p><p><blockquote>最近，苹果股票的市值接近 3 万亿美元，但很快跌破 2.9 万亿美元——因为大盘对货币紧缩政策的反应应该比之前预期的更快。</blockquote></p><p>Can shares of the Cupertino company finally find its way north in 2022 and meet the expectations of so many bulls on Wall Street? Or will bearishness take over during a year of rising interest rates and lingering inflation?</p><p><blockquote>这家库比蒂诺公司的股票最终能否在 2022 年找到北上之路，并满足华尔街众多多头的期望？或者，在利率上升和通胀挥之不去的一年里，看跌情绪会接管吗？</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1f77cd919bf55f9c7b79f631b0255910\" tg-width=\"1240\" tg-height=\"697\" referrerpolicy=\"no-referrer\"/><span>Figure 1: Apple Park in Cupertino, CA.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：加利福尼亚州库比蒂诺的苹果公园。</span></p></blockquote></p><p><b>AAPL: the bull case</b></p><p><blockquote><b>AAPL：牛市案例</b></blockquote></p><p>As Apple stock climbed viciously between late November and early December, many Wall Street experts piled on in support of “AAPL $3T”. Wedbush’s Dan Ives, for example, has been talking about the market cap milestone since our conversation in Q3 of last year, at least.</p><p><blockquote>随着苹果股价在 11 月底至 12 月初疯狂攀升，许多华尔街专家纷纷支持 “AAPL 3 万亿美元 ”。例如，至少从我们去年第三季度的谈话开始，Wedbush 的丹-艾夫斯（Dan Ives）就一直在谈论市值里程碑。</blockquote></p><p>But other analysts have also hopped on the bullish bandwagon recently. Morgan Stanley upped its price target to $200 per share in November, while the JPMorgan research team saw Apple stock heading to $3.5 trillion in market cap over the next 12 months.</p><p><blockquote>但其他分析师最近也加入了看涨行列。摩根士丹利在 11 月份将目标价上调至每股 200 美元，而摩根大通研究团队则预计苹果股票在未来 12 个月内市值将达到 3.5 万亿美元。</blockquote></p><p>One of the most vocal optimists came from the buy side. Loup’s Gene Munster thought that his previous price target had quickly become stale, and that $250 per share now seemed more reasonable. In his opinion, the multi-year opportunity in the metaverse will gain investor appreciation in the new year, which should reignite momentum that the stock had lost in the last few weeks of 2021.</p><p><blockquote>最直言不讳的乐观主义者之一来自买方。Loup 的吉恩-明斯特（Gene Munster）认为，他之前的目标价很快就过时了，现在每股 250 美元似乎更合理。他认为，元宇宙的多年机会将在新的一年获得投资者的赞赏，这应该会重新点燃该股在2021年最后几周失去的势头。</blockquote></p><p><b>AAPL: the bear case</b></p><p><blockquote><b>AAPL：熊案</b></blockquote></p><p>Despite the upbeat expectations described above, mostly supported by company-specific factors, the market rolled into 2022 with its guard up. The boogieman of the moment seems to be the Federal Reserve’s anticipated reaction to near-full employment and sticky inflation, which should lead to higher interest rates in the next several months.</p><p><blockquote>尽管上述乐观预期主要受到公司特定因素的支持，但市场进入 2022 年仍保持警惕。目前的祸根似乎是美联储对接近充分就业和粘性通胀的预期反应，这将导致未来几个月利率上升。</blockquote></p><p>I have recently explained how tighter money supply can spell trouble for stocks that trade for relatively high multiples. While AAPL is no Tesla or Rivian, the stock’s forward P/E of nearly 30 times and only modest earnings growth expectations could be a drag for share price in 2022, as investors look for better deals in value and cyclical stocks.</p><p><blockquote>我最近解释了货币供应收紧如何给市盈率相对较高的股票带来麻烦。虽然 AAPL 不是特斯拉或Rivian，但该股近 30 倍的远期市盈率和温和的盈利增长预期可能会拖累 2022 年的股价，因为投资者正在寻找价值股和周期性股票的更好交易。</blockquote></p><p><b>The Apple Maven’s take</b></p><p><blockquote><b>苹果专家的看法</b></blockquote></p><p>I continue to think that Apple is a great stock to buy and hold for the long term. Under the leadership of a CEO (and former COO) that is driven by operational excellence, the company seems to be in very good hands. Better yet, demand for Apple’s products and services, as well as consumer appreciation for the brand, seem to be at or near an all-time high.</p><p><blockquote>我仍然认为苹果是一只值得长期购买和持有的好股票。在以卓越运营为动力的首席执行官（兼前首席运营官）的领导下，公司似乎得到了很好的管理。更好的是，对苹果产品和服务的需求以及消费者对该品牌的欣赏似乎处于或接近历史最高水平。</blockquote></p><p>That said, the setup for the first few weeks or months of 2022 looks challenging to me. Apple stock climbed relentlessly in 2020, and then again last year. Aided by a spike in pandemic-driven demand for tech devices and lavish liquidity in the system, AAPL recorded one of its best three years of returns ever between 2019 and 2021.</p><p><blockquote>也就是说，2022 年头几周或几个月的设置对我来说很有挑战性。苹果股价在 2020 年持续攀升，去年又再次攀升。得益于疫情推动的技术设备需求激增以及系统中充足的流动性，苹果公司在 2019 年至 2021 年间创下了有史以来最好的三年回报之一。</blockquote></p><p>As much as the metaverse and autonomous vehicles can and likely will support the company’s financial results over the next many years, I think that AAPL stock is overdue for a breather. While shares will likely climb back above $3 trillion and head much higher from there eventually, I am not so confident that this rally will happen in the immediate future.</p><p><blockquote>尽管元宇宙和自动驾驶汽车能够并可能在未来许多年为公司的财务业绩提供支持，但我认为苹果公司的股票早该喘口气了。虽然股价可能会回升至 3 万亿美元以上，并最终从那里走得更高，但我对这种反弹会在不久的将来发生并不那么有信心。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/apple/stock/can-apple-stock-reclaim-3-trillion-and-thrive-in-2022\">TheStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/apple/stock/can-apple-stock-reclaim-3-trillion-and-thrive-in-2022","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198290127","content_text":"A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready to break through yet. Can shares reclaim the milestone soon and head higher in 2022?Recently, Apple stock flirted with $3 trillion in market cap, but quickly dipped below $2.9 trillion — as the broad market reacted to monetary tightening that should now happen more rapidly than previously expected.Can shares of the Cupertino company finally find its way north in 2022 and meet the expectations of so many bulls on Wall Street? Or will bearishness take over during a year of rising interest rates and lingering inflation?Figure 1: Apple Park in Cupertino, CA.AAPL: the bull caseAs Apple stock climbed viciously between late November and early December, many Wall Street experts piled on in support of “AAPL $3T”. Wedbush’s Dan Ives, for example, has been talking about the market cap milestone since our conversation in Q3 of last year, at least.But other analysts have also hopped on the bullish bandwagon recently. Morgan Stanley upped its price target to $200 per share in November, while the JPMorgan research team saw Apple stock heading to $3.5 trillion in market cap over the next 12 months.One of the most vocal optimists came from the buy side. Loup’s Gene Munster thought that his previous price target had quickly become stale, and that $250 per share now seemed more reasonable. In his opinion, the multi-year opportunity in the metaverse will gain investor appreciation in the new year, which should reignite momentum that the stock had lost in the last few weeks of 2021.AAPL: the bear caseDespite the upbeat expectations described above, mostly supported by company-specific factors, the market rolled into 2022 with its guard up. The boogieman of the moment seems to be the Federal Reserve’s anticipated reaction to near-full employment and sticky inflation, which should lead to higher interest rates in the next several months.I have recently explained how tighter money supply can spell trouble for stocks that trade for relatively high multiples. While AAPL is no Tesla or Rivian, the stock’s forward P/E of nearly 30 times and only modest earnings growth expectations could be a drag for share price in 2022, as investors look for better deals in value and cyclical stocks.The Apple Maven’s takeI continue to think that Apple is a great stock to buy and hold for the long term. Under the leadership of a CEO (and former COO) that is driven by operational excellence, the company seems to be in very good hands. Better yet, demand for Apple’s products and services, as well as consumer appreciation for the brand, seem to be at or near an all-time high.That said, the setup for the first few weeks or months of 2022 looks challenging to me. Apple stock climbed relentlessly in 2020, and then again last year. Aided by a spike in pandemic-driven demand for tech devices and lavish liquidity in the system, AAPL recorded one of its best three years of returns ever between 2019 and 2021.As much as the metaverse and autonomous vehicles can and likely will support the company’s financial results over the next many years, I think that AAPL stock is overdue for a breather. While shares will likely climb back above $3 trillion and head much higher from there eventually, I am not so confident that this rally will happen in the immediate future.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":2905,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694165745,"gmtCreate":1641870775663,"gmtModify":1641870776460,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Good and like&nbsp;","listText":"Good and like&nbsp;","text":"Good and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/694165745","repostId":"1162390026","repostType":4,"isVote":1,"tweetType":1,"viewCount":2461,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":694165633,"gmtCreate":1641870742975,"gmtModify":1641870772806,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Good and like&nbsp;","listText":"Good and like&nbsp;","text":"Good and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/694165633","repostId":"1198290127","repostType":4,"repost":{"id":"1198290127","kind":"news","pubTimestamp":1641702682,"share":"https://www.laohunote.com/m/news/1198290127?lang=zh_CN&edition=full","pubTime":"2022-01-09 12:31","market":"us","language":"en","title":"Can Apple Stock Reclaim $3 Trillion And Thrive In 2022?<blockquote>苹果股票能否在2022年收回3万亿美元并蓬勃发展？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1198290127","media":"TheStreet","summary":"A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready","content":"<p><html><head></head><body>A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready to break through yet. Can shares reclaim the milestone soon and head higher in 2022?</p><p><blockquote><html><head></head><body>到目前为止，3 万亿美元的市值已被证明是苹果股票似乎尚未准备好突破的上限。股价能否很快夺回里程碑并在 2022 年走高？</body></html></blockquote></p><p>Recently, Apple stock flirted with $3 trillion in market cap, but quickly dipped below $2.9 trillion — as the broad market reacted to monetary tightening that should now happen more rapidly than previously expected.</p><p><blockquote>最近，苹果股票的市值接近 3 万亿美元，但很快跌破 2.9 万亿美元——因为大盘对货币紧缩政策的反应应该比之前预期的更快。</blockquote></p><p>Can shares of the Cupertino company finally find its way north in 2022 and meet the expectations of so many bulls on Wall Street? Or will bearishness take over during a year of rising interest rates and lingering inflation?</p><p><blockquote>这家库比蒂诺公司的股票最终能否在 2022 年找到北上之路，并满足华尔街众多多头的期望？或者，在利率上升和通胀挥之不去的一年里，看跌情绪会接管吗？</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1f77cd919bf55f9c7b79f631b0255910\" tg-width=\"1240\" tg-height=\"697\" referrerpolicy=\"no-referrer\"/><span>Figure 1: Apple Park in Cupertino, CA.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：加利福尼亚州库比蒂诺的苹果公园。</span></p></blockquote></p><p><b>AAPL: the bull case</b></p><p><blockquote><b>AAPL：牛市案例</b></blockquote></p><p>As Apple stock climbed viciously between late November and early December, many Wall Street experts piled on in support of “AAPL $3T”. Wedbush’s Dan Ives, for example, has been talking about the market cap milestone since our conversation in Q3 of last year, at least.</p><p><blockquote>随着苹果股价在 11 月底至 12 月初疯狂攀升，许多华尔街专家纷纷支持 “AAPL 3 万亿美元 ”。例如，至少从我们去年第三季度的谈话开始，Wedbush 的丹-艾夫斯（Dan Ives）就一直在谈论市值里程碑。</blockquote></p><p>But other analysts have also hopped on the bullish bandwagon recently. Morgan Stanley upped its price target to $200 per share in November, while the JPMorgan research team saw Apple stock heading to $3.5 trillion in market cap over the next 12 months.</p><p><blockquote>但其他分析师最近也加入了看涨行列。摩根士丹利在 11 月份将目标价上调至每股 200 美元，而摩根大通研究团队则预计苹果股票在未来 12 个月内市值将达到 3.5 万亿美元。</blockquote></p><p>One of the most vocal optimists came from the buy side. Loup’s Gene Munster thought that his previous price target had quickly become stale, and that $250 per share now seemed more reasonable. In his opinion, the multi-year opportunity in the metaverse will gain investor appreciation in the new year, which should reignite momentum that the stock had lost in the last few weeks of 2021.</p><p><blockquote>最直言不讳的乐观主义者之一来自买方。Loup 的吉恩-明斯特（Gene Munster）认为，他之前的目标价很快就过时了，现在每股 250 美元似乎更合理。他认为，元宇宙的多年机会将在新的一年获得投资者的赞赏，这应该会重新点燃该股在2021年最后几周失去的势头。</blockquote></p><p><b>AAPL: the bear case</b></p><p><blockquote><b>AAPL：熊案</b></blockquote></p><p>Despite the upbeat expectations described above, mostly supported by company-specific factors, the market rolled into 2022 with its guard up. The boogieman of the moment seems to be the Federal Reserve’s anticipated reaction to near-full employment and sticky inflation, which should lead to higher interest rates in the next several months.</p><p><blockquote>尽管上述乐观预期主要受到公司特定因素的支持，但市场进入 2022 年仍保持警惕。目前的祸根似乎是美联储对接近充分就业和粘性通胀的预期反应，这将导致未来几个月利率上升。</blockquote></p><p>I have recently explained how tighter money supply can spell trouble for stocks that trade for relatively high multiples. While AAPL is no Tesla or Rivian, the stock’s forward P/E of nearly 30 times and only modest earnings growth expectations could be a drag for share price in 2022, as investors look for better deals in value and cyclical stocks.</p><p><blockquote>我最近解释了货币供应收紧如何给市盈率相对较高的股票带来麻烦。虽然 AAPL 不是特斯拉或Rivian，但该股近 30 倍的远期市盈率和温和的盈利增长预期可能会拖累 2022 年的股价，因为投资者正在寻找价值股和周期性股票的更好交易。</blockquote></p><p><b>The Apple Maven’s take</b></p><p><blockquote><b>苹果专家的看法</b></blockquote></p><p>I continue to think that Apple is a great stock to buy and hold for the long term. Under the leadership of a CEO (and former COO) that is driven by operational excellence, the company seems to be in very good hands. Better yet, demand for Apple’s products and services, as well as consumer appreciation for the brand, seem to be at or near an all-time high.</p><p><blockquote>我仍然认为苹果是一只值得长期购买和持有的好股票。在以卓越运营为动力的首席执行官（兼前首席运营官）的领导下，公司似乎得到了很好的管理。更好的是，对苹果产品和服务的需求以及消费者对该品牌的欣赏似乎处于或接近历史最高水平。</blockquote></p><p>That said, the setup for the first few weeks or months of 2022 looks challenging to me. Apple stock climbed relentlessly in 2020, and then again last year. Aided by a spike in pandemic-driven demand for tech devices and lavish liquidity in the system, AAPL recorded one of its best three years of returns ever between 2019 and 2021.</p><p><blockquote>也就是说，2022 年头几周或几个月的设置对我来说很有挑战性。苹果股价在 2020 年持续攀升，去年又再次攀升。得益于疫情推动的技术设备需求激增以及系统中充足的流动性，苹果公司在 2019 年至 2021 年间创下了有史以来最好的三年回报之一。</blockquote></p><p>As much as the metaverse and autonomous vehicles can and likely will support the company’s financial results over the next many years, I think that AAPL stock is overdue for a breather. While shares will likely climb back above $3 trillion and head much higher from there eventually, I am not so confident that this rally will happen in the immediate future.</p><p><blockquote>尽管元宇宙和自动驾驶汽车能够并可能在未来许多年为公司的财务业绩提供支持，但我认为苹果公司的股票早该喘口气了。虽然股价可能会回升至 3 万亿美元以上，并最终从那里走得更高，但我对这种反弹会在不久的将来发生并不那么有信心。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can Apple Stock Reclaim $3 Trillion And Thrive In 2022?<blockquote>苹果股票能否在2022年收回3万亿美元并蓬勃发展？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan Apple Stock Reclaim $3 Trillion And Thrive In 2022?<blockquote>苹果股票能否在2022年收回3万亿美元并蓬勃发展？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2022-01-09 12:31</span>\n</p>\n</h4>\n</header>\n<article>\n<p><html><head></head><body>A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready to break through yet. Can shares reclaim the milestone soon and head higher in 2022?</p><p><blockquote><html><head></head><body>到目前为止，3 万亿美元的市值已被证明是苹果股票似乎尚未准备好突破的上限。股价能否很快夺回里程碑并在 2022 年走高？</body></html></blockquote></p><p>Recently, Apple stock flirted with $3 trillion in market cap, but quickly dipped below $2.9 trillion — as the broad market reacted to monetary tightening that should now happen more rapidly than previously expected.</p><p><blockquote>最近，苹果股票的市值接近 3 万亿美元，但很快跌破 2.9 万亿美元——因为大盘对货币紧缩政策的反应应该比之前预期的更快。</blockquote></p><p>Can shares of the Cupertino company finally find its way north in 2022 and meet the expectations of so many bulls on Wall Street? Or will bearishness take over during a year of rising interest rates and lingering inflation?</p><p><blockquote>这家库比蒂诺公司的股票最终能否在 2022 年找到北上之路，并满足华尔街众多多头的期望？或者，在利率上升和通胀挥之不去的一年里，看跌情绪会接管吗？</blockquote></p><p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1f77cd919bf55f9c7b79f631b0255910\" tg-width=\"1240\" tg-height=\"697\" referrerpolicy=\"no-referrer\"/><span>Figure 1: Apple Park in Cupertino, CA.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图1：加利福尼亚州库比蒂诺的苹果公园。</span></p></blockquote></p><p><b>AAPL: the bull case</b></p><p><blockquote><b>AAPL：牛市案例</b></blockquote></p><p>As Apple stock climbed viciously between late November and early December, many Wall Street experts piled on in support of “AAPL $3T”. Wedbush’s Dan Ives, for example, has been talking about the market cap milestone since our conversation in Q3 of last year, at least.</p><p><blockquote>随着苹果股价在 11 月底至 12 月初疯狂攀升，许多华尔街专家纷纷支持 “AAPL 3 万亿美元 ”。例如，至少从我们去年第三季度的谈话开始，Wedbush 的丹-艾夫斯（Dan Ives）就一直在谈论市值里程碑。</blockquote></p><p>But other analysts have also hopped on the bullish bandwagon recently. Morgan Stanley upped its price target to $200 per share in November, while the JPMorgan research team saw Apple stock heading to $3.5 trillion in market cap over the next 12 months.</p><p><blockquote>但其他分析师最近也加入了看涨行列。摩根士丹利在 11 月份将目标价上调至每股 200 美元，而摩根大通研究团队则预计苹果股票在未来 12 个月内市值将达到 3.5 万亿美元。</blockquote></p><p>One of the most vocal optimists came from the buy side. Loup’s Gene Munster thought that his previous price target had quickly become stale, and that $250 per share now seemed more reasonable. In his opinion, the multi-year opportunity in the metaverse will gain investor appreciation in the new year, which should reignite momentum that the stock had lost in the last few weeks of 2021.</p><p><blockquote>最直言不讳的乐观主义者之一来自买方。Loup 的吉恩-明斯特（Gene Munster）认为，他之前的目标价很快就过时了，现在每股 250 美元似乎更合理。他认为，元宇宙的多年机会将在新的一年获得投资者的赞赏，这应该会重新点燃该股在2021年最后几周失去的势头。</blockquote></p><p><b>AAPL: the bear case</b></p><p><blockquote><b>AAPL：熊案</b></blockquote></p><p>Despite the upbeat expectations described above, mostly supported by company-specific factors, the market rolled into 2022 with its guard up. The boogieman of the moment seems to be the Federal Reserve’s anticipated reaction to near-full employment and sticky inflation, which should lead to higher interest rates in the next several months.</p><p><blockquote>尽管上述乐观预期主要受到公司特定因素的支持，但市场进入 2022 年仍保持警惕。目前的祸根似乎是美联储对接近充分就业和粘性通胀的预期反应，这将导致未来几个月利率上升。</blockquote></p><p>I have recently explained how tighter money supply can spell trouble for stocks that trade for relatively high multiples. While AAPL is no Tesla or Rivian, the stock’s forward P/E of nearly 30 times and only modest earnings growth expectations could be a drag for share price in 2022, as investors look for better deals in value and cyclical stocks.</p><p><blockquote>我最近解释了货币供应收紧如何给市盈率相对较高的股票带来麻烦。虽然 AAPL 不是特斯拉或Rivian，但该股近 30 倍的远期市盈率和温和的盈利增长预期可能会拖累 2022 年的股价，因为投资者正在寻找价值股和周期性股票的更好交易。</blockquote></p><p><b>The Apple Maven’s take</b></p><p><blockquote><b>苹果专家的看法</b></blockquote></p><p>I continue to think that Apple is a great stock to buy and hold for the long term. Under the leadership of a CEO (and former COO) that is driven by operational excellence, the company seems to be in very good hands. Better yet, demand for Apple’s products and services, as well as consumer appreciation for the brand, seem to be at or near an all-time high.</p><p><blockquote>我仍然认为苹果是一只值得长期购买和持有的好股票。在以卓越运营为动力的首席执行官（兼前首席运营官）的领导下，公司似乎得到了很好的管理。更好的是，对苹果产品和服务的需求以及消费者对该品牌的欣赏似乎处于或接近历史最高水平。</blockquote></p><p>That said, the setup for the first few weeks or months of 2022 looks challenging to me. Apple stock climbed relentlessly in 2020, and then again last year. Aided by a spike in pandemic-driven demand for tech devices and lavish liquidity in the system, AAPL recorded one of its best three years of returns ever between 2019 and 2021.</p><p><blockquote>也就是说，2022 年头几周或几个月的设置对我来说很有挑战性。苹果股价在 2020 年持续攀升，去年又再次攀升。得益于疫情推动的技术设备需求激增以及系统中充足的流动性，苹果公司在 2019 年至 2021 年间创下了有史以来最好的三年回报之一。</blockquote></p><p>As much as the metaverse and autonomous vehicles can and likely will support the company’s financial results over the next many years, I think that AAPL stock is overdue for a breather. While shares will likely climb back above $3 trillion and head much higher from there eventually, I am not so confident that this rally will happen in the immediate future.</p><p><blockquote>尽管元宇宙和自动驾驶汽车能够并可能在未来许多年为公司的财务业绩提供支持，但我认为苹果公司的股票早该喘口气了。虽然股价可能会回升至 3 万亿美元以上，并最终从那里走得更高，但我对这种反弹会在不久的将来发生并不那么有信心。</blockquote></p><p></body></html></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/apple/stock/can-apple-stock-reclaim-3-trillion-and-thrive-in-2022\">TheStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/apple/stock/can-apple-stock-reclaim-3-trillion-and-thrive-in-2022","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198290127","content_text":"A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready to break through yet. Can shares reclaim the milestone soon and head higher in 2022?Recently, Apple stock flirted with $3 trillion in market cap, but quickly dipped below $2.9 trillion — as the broad market reacted to monetary tightening that should now happen more rapidly than previously expected.Can shares of the Cupertino company finally find its way north in 2022 and meet the expectations of so many bulls on Wall Street? Or will bearishness take over during a year of rising interest rates and lingering inflation?Figure 1: Apple Park in Cupertino, CA.AAPL: the bull caseAs Apple stock climbed viciously between late November and early December, many Wall Street experts piled on in support of “AAPL $3T”. Wedbush’s Dan Ives, for example, has been talking about the market cap milestone since our conversation in Q3 of last year, at least.But other analysts have also hopped on the bullish bandwagon recently. Morgan Stanley upped its price target to $200 per share in November, while the JPMorgan research team saw Apple stock heading to $3.5 trillion in market cap over the next 12 months.One of the most vocal optimists came from the buy side. Loup’s Gene Munster thought that his previous price target had quickly become stale, and that $250 per share now seemed more reasonable. In his opinion, the multi-year opportunity in the metaverse will gain investor appreciation in the new year, which should reignite momentum that the stock had lost in the last few weeks of 2021.AAPL: the bear caseDespite the upbeat expectations described above, mostly supported by company-specific factors, the market rolled into 2022 with its guard up. The boogieman of the moment seems to be the Federal Reserve’s anticipated reaction to near-full employment and sticky inflation, which should lead to higher interest rates in the next several months.I have recently explained how tighter money supply can spell trouble for stocks that trade for relatively high multiples. While AAPL is no Tesla or Rivian, the stock’s forward P/E of nearly 30 times and only modest earnings growth expectations could be a drag for share price in 2022, as investors look for better deals in value and cyclical stocks.The Apple Maven’s takeI continue to think that Apple is a great stock to buy and hold for the long term. Under the leadership of a CEO (and former COO) that is driven by operational excellence, the company seems to be in very good hands. Better yet, demand for Apple’s products and services, as well as consumer appreciation for the brand, seem to be at or near an all-time high.That said, the setup for the first few weeks or months of 2022 looks challenging to me. Apple stock climbed relentlessly in 2020, and then again last year. Aided by a spike in pandemic-driven demand for tech devices and lavish liquidity in the system, AAPL recorded one of its best three years of returns ever between 2019 and 2021.As much as the metaverse and autonomous vehicles can and likely will support the company’s financial results over the next many years, I think that AAPL stock is overdue for a breather. While shares will likely climb back above $3 trillion and head much higher from there eventually, I am not so confident that this rally will happen in the immediate future.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":1231,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699746938,"gmtCreate":1639912234161,"gmtModify":1639912234888,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/699746938","repostId":"1161245886","repostType":4,"repost":{"id":"1161245886","kind":"news","pubTimestamp":1639806035,"share":"https://www.laohunote.com/m/news/1161245886?lang=zh_CN&edition=full","pubTime":"2021-12-18 13:40","market":"us","language":"en","title":"Wedbush's Dan Ives: Don't throw in the towel on tech<blockquote>韦德布什的丹·艾夫斯：不要放弃科技</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1161245886","media":"Seeking Alpha","summary":"Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.\"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.Calling the current era \"a fourth industrial revolution,\" Ives backed such stocks as $CyberArk Software $, $Palo Alto Networks $, $Zscaler $, $NVIDIA $ and $Apple $.\"This is an opportunity, not the start of a downtrend ","content":"<p>Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.</p><p><blockquote>韦德布什证券董事总经理丹·艾夫斯建议投资者坚持投资科技股，尽管美联储加息可能会出现潜在的估值紧缩。</blockquote></p><p> \"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.</p><p><blockquote>“现在不是放弃科技的时候，”他周五对 CNBC 表示。</blockquote></p><p> Calling the current era \"a fourth industrial revolution,\" Ives backed such stocks as <a href=\"https://laohu8.com/S/CYBR\">CyberArk Software </a>, <a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks </a>, <a href=\"https://laohu8.com/S/ZS\">Zscaler </a>, <a href=\"https://laohu8.com/S/NVDA\">NVIDIA </a> and <a href=\"https://laohu8.com/S/AAPL\">Apple </a>.</p><p><blockquote>艾夫斯将当前时代称为“第四次工业革命”，他支持以下股票：<a href=\"https://laohu8.com/S/CYBR\">赛博方舟软件</a>,<a href=\"https://laohu8.com/S/PANW\">帕洛阿尔托网络</a>,<a href=\"https://laohu8.com/S/ZS\">缩放器</a>,<a href=\"https://laohu8.com/S/NVDA\">英伟达</a>和<a href=\"https://laohu8.com/S/AAPL\">苹果</a>.</blockquote></p><p> \"This is an opportunity, not the start of a downtrend for tech,\" he said.</p><p><blockquote>“这是一个机会，而不是科技下行趋势的开始，”他说。</blockquote></p><p> Ives argued that a large number of tech names will see significant growth in coming years thanks to heavy spending on technologies like cybersecurity, 5G and further moves into the cloud.</p><p><blockquote>艾夫斯认为，由于在网络安全、5G等技术上的巨额支出以及进一步向云迁移，大量科技公司将在未来几年实现显着增长。</blockquote></p><p> He estimated that this \"digital transformation\" would fuel another $2T in spending over the next six to seven years.</p><p><blockquote>他估计，这种“数字化转型”将在未来六到七年内增加 2 万亿美元的支出。</blockquote></p><p> That said, Ives warned investors that they had to be selective with their portfolios, as some stocks will lose momentum once the massive pandemic-related stimulus comes to an end.</p><p><blockquote>尽管如此，艾夫斯警告投资者，他们必须对投资组合进行选择性，因为一旦与大流行相关的大规模刺激措施结束，一些股票将失去动力。</blockquote></p><p> \"You have to separate the winners from the losers and the long-term winners versus the ones that benefited from the pandemic,\" he said.</p><p><blockquote>他说：“你必须区分赢家和输家，区分长期赢家和从疫情中受益的人。”</blockquote></p><p> Rather, Ives suggested investors \"double down on their winners.\"</p><p><blockquote>相反，艾夫斯建议投资者“加倍押注赢家”。</blockquote></p><p> Looking at some of the stocks mentioned by Ives, NVDA has done by far the best in 2021, more than doubling over the course of the year. ZS and PANW have both risen nearly 50%. AAPL lags behind its smaller rivals, although it has rallied about 30% for 2021.</p><p><blockquote>从艾夫斯提到的一些股票来看，NVDA 在 2021 年的表现是迄今为止最好的，一年内上涨了一倍多。ZS 和 PANW 均上涨近 50%。AAPL 落后于规模较小的竞争对手，尽管它在 2021 年上涨了约 30%。</blockquote></p><p> The main laggard in the group is CYBR, which is basically flat on the year:</p><p><blockquote>集团中主要落后的是CYBR，同比基本持平：</blockquote></p><p> <img src=\"https://static.tigerbbs.com/25aa45389fe8b89d41006f304e02894e\" tg-width=\"1201\" tg-height=\"405\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wedbush's Dan Ives: Don't throw in the towel on tech<blockquote>韦德布什的丹·艾夫斯：不要放弃科技</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWedbush's Dan Ives: Don't throw in the towel on tech<blockquote>韦德布什的丹·艾夫斯：不要放弃科技</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-12-18 13:40</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.</p><p><blockquote>韦德布什证券董事总经理丹·艾夫斯建议投资者坚持投资科技股，尽管美联储加息可能会出现潜在的估值紧缩。</blockquote></p><p> \"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.</p><p><blockquote>“现在不是放弃科技的时候，”他周五对 CNBC 表示。</blockquote></p><p> Calling the current era \"a fourth industrial revolution,\" Ives backed such stocks as <a href=\"https://laohu8.com/S/CYBR\">CyberArk Software </a>, <a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks </a>, <a href=\"https://laohu8.com/S/ZS\">Zscaler </a>, <a href=\"https://laohu8.com/S/NVDA\">NVIDIA </a> and <a href=\"https://laohu8.com/S/AAPL\">Apple </a>.</p><p><blockquote>艾夫斯将当前时代称为“第四次工业革命”，他支持以下股票：<a href=\"https://laohu8.com/S/CYBR\">赛博方舟软件</a>,<a href=\"https://laohu8.com/S/PANW\">帕洛阿尔托网络</a>,<a href=\"https://laohu8.com/S/ZS\">缩放器</a>,<a href=\"https://laohu8.com/S/NVDA\">英伟达</a>和<a href=\"https://laohu8.com/S/AAPL\">苹果</a>.</blockquote></p><p> \"This is an opportunity, not the start of a downtrend for tech,\" he said.</p><p><blockquote>“这是一个机会，而不是科技下行趋势的开始，”他说。</blockquote></p><p> Ives argued that a large number of tech names will see significant growth in coming years thanks to heavy spending on technologies like cybersecurity, 5G and further moves into the cloud.</p><p><blockquote>艾夫斯认为，由于在网络安全、5G等技术上的巨额支出以及进一步向云迁移，大量科技公司将在未来几年实现显着增长。</blockquote></p><p> He estimated that this \"digital transformation\" would fuel another $2T in spending over the next six to seven years.</p><p><blockquote>他估计，这种“数字化转型”将在未来六到七年内增加 2 万亿美元的支出。</blockquote></p><p> That said, Ives warned investors that they had to be selective with their portfolios, as some stocks will lose momentum once the massive pandemic-related stimulus comes to an end.</p><p><blockquote>尽管如此，艾夫斯警告投资者，他们必须对投资组合进行选择性，因为一旦与大流行相关的大规模刺激措施结束，一些股票将失去动力。</blockquote></p><p> \"You have to separate the winners from the losers and the long-term winners versus the ones that benefited from the pandemic,\" he said.</p><p><blockquote>他说：“你必须区分赢家和输家，区分长期赢家和从疫情中受益的人。”</blockquote></p><p> Rather, Ives suggested investors \"double down on their winners.\"</p><p><blockquote>相反，艾夫斯建议投资者“加倍押注赢家”。</blockquote></p><p> Looking at some of the stocks mentioned by Ives, NVDA has done by far the best in 2021, more than doubling over the course of the year. ZS and PANW have both risen nearly 50%. AAPL lags behind its smaller rivals, although it has rallied about 30% for 2021.</p><p><blockquote>从艾夫斯提到的一些股票来看，NVDA 在 2021 年的表现是迄今为止最好的，一年内上涨了一倍多。ZS 和 PANW 均上涨近 50%。AAPL 落后于规模较小的竞争对手，尽管它在 2021 年上涨了约 30%。</blockquote></p><p> The main laggard in the group is CYBR, which is basically flat on the year:</p><p><blockquote>集团中主要落后的是CYBR，同比基本持平：</blockquote></p><p> <img src=\"https://static.tigerbbs.com/25aa45389fe8b89d41006f304e02894e\" tg-width=\"1201\" tg-height=\"405\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3781354-dont-throw-in-the-towel-on-tech-wedbushs-dan-ives\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZS":"Zscaler Inc.","NVDA":"英伟达","PANW":"Palo Alto Networks","CYBR":"Cyber-Ark Software"},"source_url":"https://seekingalpha.com/news/3781354-dont-throw-in-the-towel-on-tech-wedbushs-dan-ives","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161245886","content_text":"Wedbush Securities managing director Dan Ives advised investors to stick with technology stocks despite the potential valuation crunch that could happen as the Federal Reserve raises interest rates.\n\"This is not the time to throw in the white towel on tech,\" he told CNBC on Friday.\nCalling the current era \"a fourth industrial revolution,\" Ives backed such stocks as CyberArk Software , Palo Alto Networks , Zscaler , NVIDIA  and Apple .\n\"This is an opportunity, not the start of a downtrend for tech,\" he said.\nIves argued that a large number of tech names will see significant growth in coming years thanks to heavy spending on technologies like cybersecurity, 5G and further moves into the cloud.\nHe estimated that this \"digital transformation\" would fuel another $2T in spending over the next six to seven years.\nThat said, Ives warned investors that they had to be selective with their portfolios, as some stocks will lose momentum once the massive pandemic-related stimulus comes to an end.\n\"You have to separate the winners from the losers and the long-term winners versus the ones that benefited from the pandemic,\" he said.\nRather, Ives suggested investors \"double down on their winners.\"\nLooking at some of the stocks mentioned by Ives, NVDA has done by far the best in 2021, more than doubling over the course of the year. ZS and PANW have both risen nearly 50%. AAPL lags behind its smaller rivals, although it has rallied about 30% for 2021.\nThe main laggard in the group is CYBR, which is basically flat on the year:","news_type":1,"symbols_score_info":{"CYBR":0.9,"NVDA":0.9,"PANW":0.9,"ZS":0.9}},"isVote":1,"tweetType":1,"viewCount":1223,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699746002,"gmtCreate":1639912187277,"gmtModify":1639912188046,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Good and like&nbsp;","listText":"Good and like&nbsp;","text":"Good and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699746002","repostId":"2192903795","repostType":4,"isVote":1,"tweetType":1,"viewCount":910,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699748864,"gmtCreate":1639912093161,"gmtModify":1639912093917,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Good and like&nbsp;","listText":"Good and like&nbsp;","text":"Good and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699748864","repostId":"2192035909","repostType":4,"isVote":1,"tweetType":1,"viewCount":1492,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690723142,"gmtCreate":1639710708828,"gmtModify":1639710709570,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/690723142","repostId":"1172405131","repostType":4,"isVote":1,"tweetType":1,"viewCount":1669,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690729556,"gmtCreate":1639710686989,"gmtModify":1639710687734,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690729556","repostId":"1177842222","repostType":4,"isVote":1,"tweetType":1,"viewCount":1530,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":600134713,"gmtCreate":1638085346744,"gmtModify":1638085414184,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":13,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/600134713","repostId":"1153242523","repostType":4,"repost":{"id":"1153242523","kind":"news","pubTimestamp":1638063498,"share":"https://www.laohunote.com/m/news/1153242523?lang=zh_CN&edition=full","pubTime":"2021-11-28 09:38","market":"us","language":"en","title":"US IPO Week Ahead: December kicks off with a 1 IPO week<blockquote>美国 IPO 周即将到来：12 月以 1 IPO 周拉开帷幕</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1153242523","media":"Renaissance Capital","summary":"The US IPO market is taking a breather after the holiday week, with just one IPO scheduled to raise ","content":"<p>The US IPO market is taking a breather after the holiday week, with just one IPO scheduled to raise $30 million in the first week of December.</p><p><blockquote>假期周后，美国IPO市场正在喘口气，12月第一周只有一笔IPO计划筹集3000万美元。</blockquote></p><p> While the calendar is quiet at the moment, several IPOs are eligible to launch on Monday, including Indian IT services provider&nbsp;<b>Coforge</b>&nbsp;(CFRG.RC), cloud infrastructure platform&nbsp;<b>HashiCorp</b>&nbsp;(HCP), luxury fashion e-tailer&nbsp;<b>Rue Gilt Group</b>&nbsp;(RGG), rugged apparel brand&nbsp;<b>5.11 ABR</b>(VXI), and Florida-based insurer&nbsp;<b>TypTapInsurance Group</b>&nbsp;(TYTP).</p><p><blockquote>虽然目前日历平静，但有几家 IPO 有资格在周一启动，其中包括印度 IT 服务提供商<b>锻造</b>(CFRG.RC)，云基础设施平台<b>哈希公司</b>(HCP)，奢侈时尚电子零售商<b>吉尔特街集团</b>(RGG)，坚固的服装品牌<b>5月11日</b>(VXI) 和佛罗里达州保险公司<b>TYPTA保险集团</b>（TYTP）。</blockquote></p><p> Phase 1-ready biotech&nbsp;<b>Nuvectis Pharma</b>&nbsp;(NVCT) plans to raise $30 million at a $160 million market cap. The company is initially focused the development of innovative precision medicines for the treatment of serious unmet medical needs in oncology. Nuvectis is currently developing two preclinical candidates, with its lead candidate expected to begin a Phase 1 trial in the 4Q21.</p><p><blockquote>第一阶段就绪的生物技术<b>Nuvectis制药</b>（NVCT）计划以1.6亿美元的市值筹集3000万美元。该公司最初专注于开发创新的精准药物，以治疗肿瘤学中严重未满足的医疗需求。Nuvectis 目前正在开发两种临床前候选药物，其主要候选药物预计将在2021年第四季度开始 1 期试验。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/ebedc817c5c3858bec4f16c6152bfce8\" tg-width=\"936\" tg-height=\"163\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Street research is expected to 12 companies in the week ahead, and lock-up periods will be expiring for up to four companies. For access to Street research and lock-up dates,sign up for a free trial of IPO Pro.</p><p><blockquote>Street research 预计未来一周将对 12 家公司进行调查，多达 4 家公司的禁售期将到期。要获得街头研究和锁定日期， 注册免费试用IPO Pro。</blockquote></p><p> <b>IPO Market Snapshot</b></p><p><blockquote><b>IPO市场快照</b></blockquote></p><p> The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 11/24/2021, the Renaissance IPO Index was down 1.1% year-to-date, while the S&amp;P 500 was up 25.2%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Snowflake (SNOW) and Moderna (MRNA). The Renaissance International IPO Index was down 22.4% year-to-date, while the ACWX was up 7.4%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Meituan-Dianping and SoftBank.</p><p><blockquote>文艺复兴IPO指数是新上市公司的市值加权篮子。截至2021年11月24日，文艺复兴IPO指数年初至今下跌1.1%，而标普500上涨25.2%。Renaissance Capital 的 IPO ETF（纽约证券交易所股票代码：IPO）追踪该指数，持有量最大的 ETF 包括 Snowflake (SNOW) 和 Moderna (MRNA)。Renaissance International IPO 指数今年迄今下跌 22.4%，而 ACWX 指数上涨 7.4%。Renaissance Capital 的国际 IPO ETF（纽约证券交易所股票代码：IPOS）追踪该指数，持有量最大的 ETF 包括美团-W大众点评和软银。</blockquote></p><p></p>","source":"lsy1603787993745","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>US IPO Week Ahead: December kicks off with a 1 IPO week<blockquote>美国 IPO 周即将到来：12 月以 1 IPO 周拉开帷幕</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUS IPO Week Ahead: December kicks off with a 1 IPO week<blockquote>美国 IPO 周即将到来：12 月以 1 IPO 周拉开帷幕</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Renaissance Capital</strong><span class=\"h-time small\">2021-11-28 09:38</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The US IPO market is taking a breather after the holiday week, with just one IPO scheduled to raise $30 million in the first week of December.</p><p><blockquote>假期周后，美国IPO市场正在喘口气，12月第一周只有一笔IPO计划筹集3000万美元。</blockquote></p><p> While the calendar is quiet at the moment, several IPOs are eligible to launch on Monday, including Indian IT services provider&nbsp;<b>Coforge</b>&nbsp;(CFRG.RC), cloud infrastructure platform&nbsp;<b>HashiCorp</b>&nbsp;(HCP), luxury fashion e-tailer&nbsp;<b>Rue Gilt Group</b>&nbsp;(RGG), rugged apparel brand&nbsp;<b>5.11 ABR</b>(VXI), and Florida-based insurer&nbsp;<b>TypTapInsurance Group</b>&nbsp;(TYTP).</p><p><blockquote>虽然目前日历平静，但有几家 IPO 有资格在周一启动，其中包括印度 IT 服务提供商<b>锻造</b>(CFRG.RC)，云基础设施平台<b>哈希公司</b>(HCP)，奢侈时尚电子零售商<b>吉尔特街集团</b>(RGG)，坚固的服装品牌<b>5月11日</b>(VXI) 和佛罗里达州保险公司<b>TYPTA保险集团</b>（TYTP）。</blockquote></p><p> Phase 1-ready biotech&nbsp;<b>Nuvectis Pharma</b>&nbsp;(NVCT) plans to raise $30 million at a $160 million market cap. The company is initially focused the development of innovative precision medicines for the treatment of serious unmet medical needs in oncology. Nuvectis is currently developing two preclinical candidates, with its lead candidate expected to begin a Phase 1 trial in the 4Q21.</p><p><blockquote>第一阶段就绪的生物技术<b>Nuvectis制药</b>（NVCT）计划以1.6亿美元的市值筹集3000万美元。该公司最初专注于开发创新的精准药物，以治疗肿瘤学中严重未满足的医疗需求。Nuvectis 目前正在开发两种临床前候选药物，其主要候选药物预计将在2021年第四季度开始 1 期试验。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/ebedc817c5c3858bec4f16c6152bfce8\" tg-width=\"936\" tg-height=\"163\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Street research is expected to 12 companies in the week ahead, and lock-up periods will be expiring for up to four companies. For access to Street research and lock-up dates,sign up for a free trial of IPO Pro.</p><p><blockquote>Street research 预计未来一周将对 12 家公司进行调查，多达 4 家公司的禁售期将到期。要获得街头研究和锁定日期， 注册免费试用IPO Pro。</blockquote></p><p> <b>IPO Market Snapshot</b></p><p><blockquote><b>IPO市场快照</b></blockquote></p><p> The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 11/24/2021, the Renaissance IPO Index was down 1.1% year-to-date, while the S&amp;P 500 was up 25.2%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Snowflake (SNOW) and Moderna (MRNA). The Renaissance International IPO Index was down 22.4% year-to-date, while the ACWX was up 7.4%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Meituan-Dianping and SoftBank.</p><p><blockquote>文艺复兴IPO指数是新上市公司的市值加权篮子。截至2021年11月24日，文艺复兴IPO指数年初至今下跌1.1%，而标普500上涨25.2%。Renaissance Capital 的 IPO ETF（纽约证券交易所股票代码：IPO）追踪该指数，持有量最大的 ETF 包括 Snowflake (SNOW) 和 Moderna (MRNA)。Renaissance International IPO 指数今年迄今下跌 22.4%，而 ACWX 指数上涨 7.4%。Renaissance Capital 的国际 IPO ETF（纽约证券交易所股票代码：IPOS）追踪该指数，持有量最大的 ETF 包括美团-W大众点评和软银。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.renaissancecapital.com/IPO-Center/News/89065/US-IPO-Week-Ahead-December-kicks-off-with-a-1-IPO-week\">Renaissance Capital</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVCT":"Nuvectis Pharma, Inc."},"source_url":"https://www.renaissancecapital.com/IPO-Center/News/89065/US-IPO-Week-Ahead-December-kicks-off-with-a-1-IPO-week","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153242523","content_text":"The US IPO market is taking a breather after the holiday week, with just one IPO scheduled to raise $30 million in the first week of December.\nWhile the calendar is quiet at the moment, several IPOs are eligible to launch on Monday, including Indian IT services provider Coforge (CFRG.RC), cloud infrastructure platform HashiCorp (HCP), luxury fashion e-tailer Rue Gilt Group (RGG), rugged apparel brand 5.11 ABR(VXI), and Florida-based insurer TypTapInsurance Group (TYTP).\nPhase 1-ready biotech Nuvectis Pharma (NVCT) plans to raise $30 million at a $160 million market cap. The company is initially focused the development of innovative precision medicines for the treatment of serious unmet medical needs in oncology. Nuvectis is currently developing two preclinical candidates, with its lead candidate expected to begin a Phase 1 trial in the 4Q21.\n\nStreet research is expected to 12 companies in the week ahead, and lock-up periods will be expiring for up to four companies. For access to Street research and lock-up dates,sign up for a free trial of IPO Pro.\nIPO Market Snapshot\nThe Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 11/24/2021, the Renaissance IPO Index was down 1.1% year-to-date, while the S&P 500 was up 25.2%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Snowflake (SNOW) and Moderna (MRNA). The Renaissance International IPO Index was down 22.4% year-to-date, while the ACWX was up 7.4%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Meituan-Dianping and SoftBank.","news_type":1,"symbols_score_info":{"NVCT":0.9}},"isVote":1,"tweetType":1,"viewCount":651,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":849663890,"gmtCreate":1635753108627,"gmtModify":1635753108863,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Good and like&nbsp;","listText":"Good and like&nbsp;","text":"Good and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/849663890","repostId":"2180275337","repostType":4,"repost":{"id":"2180275337","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga Earnings","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1635751276,"share":"https://www.laohunote.com/m/news/2180275337?lang=zh_CN&edition=full","pubTime":"2021-11-01 15:21","market":"us","language":"en","title":"5 Stocks To Watch For November 1, 2021<blockquote>2021 年 11 月 1 日值得关注的 5 只股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=2180275337","media":"Benzinga Earnings","summary":"Some of the stocks that may grab investor focus today are:\n\tWall Street expects  PG&amp;E Corporation  (NYSE: PCG) to report quarterly earnings at $0.26 per share on revenue of $5.37 billion before the opening bell. PG&amp;E shares rose 0.6% to $11.67 in after-hours trading.\n","content":"<p>Some of the stocks that may grab investor focus today are:</p><p><blockquote>今天可能吸引投资者关注的一些股票是：</blockquote></p><p> <ul>  <li>Wall Street expects <b>PG&amp;E Corporation </b> (NYSE:PCG) to report quarterly earnings at $0.26 per share on revenue of $5.37 billion before the opening bell. PG&amp;E shares rose 0.6% to $11.67 in after-hours trading.</li>  <li><b>Xpeng Inc - ADR </b>(NYSE:XPEV) said it delivered 10,138 vehicles in October, a 233% surge year-on-year, despite the semiconductor shortage. Xpeng shares rose 0.4% to $46.80 in the after-hours trading session.</li>  <li>Analysts are expecting <b>McKesson Corporation </b> (NYSE:MCK) to have earned $4.62 per share on revenue of $63.12 billion for the latest quarter. The company will release earnings after the markets clsoe. McKesson shares rose 1.4% to close at $207.88 on Friday.</li> </ul> <ul>  <li>After the opening bell, <b>Clorox Co </b> (NYSE:CLX) is projected to post quarterly earnings at $1.03 per share on revenue of $1.70 billion. Clorox shares gained 0.1% to $163.10 in after-hours trading.</li>  <li>Analysts expect <b>ON Semiconductor Corp </b> (NASDAQ:ON) to post quarterly earnings at $0.74 per share on revenue of $1.71 billion before the opening bell. ON Semiconductor shares rose 1.8% to $48.94 in after-hours trading.</li> </ul></p><p><blockquote><ul><li>华尔街预期<b>PG&amp;E公司</b>（纽约证券交易所股票代码：PCG）将公布季度收益，每股 0.26 美元，开盘前营收为 53.7 亿美元。PG&amp;E 股价在盘后交易中上涨 0.6%，至 11.67 美元。</li><li><b>小鹏汽车 - ADR</b>（纽约证券交易所股票代码：XPEV）表示，尽管半导体短缺，但10月份仍交付了10,138辆汽车，同比激增233%。小鹏汽车股价在盘后交易时段上涨 0.4%，至 46.80 美元。</li><li>分析师预计<b>麦克森公司</b>（纽约证券交易所股票代码：MCK）最新季度每股收益为 4.62 美元，营收为 631.2 亿美元。该公司将在 clsoe 上市后发布收益。McKesson 股价周五上涨 1.4%，收于 207.88 美元。</li></ul><ul><li>开场钟声过后，<b>高乐氏公司</b>（纽约证券交易所股票代码：CLX）预计季度收益为每股 1.03 美元，营收为 17.0 亿美元。高乐氏股价在盘后交易中上涨 0.1%，至 163.10 美元。</li><li>分析师预计<b>安森美半导体</b>（纳斯达克股票代码：ON）公布季度收益为每股 0.74 美元，开盘前营收为 17.1 亿美元。安森美半导体股价在盘后交易中上涨 1.8%，至 48.94 美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks To Watch For November 1, 2021<blockquote>2021 年 11 月 1 日值得关注的 5 只股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks To Watch For November 1, 2021<blockquote>2021 年 11 月 1 日值得关注的 5 只股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time smaller\">2021-11-01 15:21</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>Some of the stocks that may grab investor focus today are:</p><p><blockquote>今天可能吸引投资者关注的一些股票是：</blockquote></p><p> <ul>  <li>Wall Street expects <b>PG&amp;E Corporation </b> (NYSE:PCG) to report quarterly earnings at $0.26 per share on revenue of $5.37 billion before the opening bell. PG&amp;E shares rose 0.6% to $11.67 in after-hours trading.</li>  <li><b>Xpeng Inc - ADR </b>(NYSE:XPEV) said it delivered 10,138 vehicles in October, a 233% surge year-on-year, despite the semiconductor shortage. Xpeng shares rose 0.4% to $46.80 in the after-hours trading session.</li>  <li>Analysts are expecting <b>McKesson Corporation </b> (NYSE:MCK) to have earned $4.62 per share on revenue of $63.12 billion for the latest quarter. The company will release earnings after the markets clsoe. McKesson shares rose 1.4% to close at $207.88 on Friday.</li> </ul> <ul>  <li>After the opening bell, <b>Clorox Co </b> (NYSE:CLX) is projected to post quarterly earnings at $1.03 per share on revenue of $1.70 billion. Clorox shares gained 0.1% to $163.10 in after-hours trading.</li>  <li>Analysts expect <b>ON Semiconductor Corp </b> (NASDAQ:ON) to post quarterly earnings at $0.74 per share on revenue of $1.71 billion before the opening bell. ON Semiconductor shares rose 1.8% to $48.94 in after-hours trading.</li> </ul></p><p><blockquote><ul><li>华尔街预期<b>PG&amp;E公司</b>（纽约证券交易所股票代码：PCG）将公布季度收益，每股 0.26 美元，开盘前营收为 53.7 亿美元。PG&amp;E 股价在盘后交易中上涨 0.6%，至 11.67 美元。</li><li><b>小鹏汽车 - ADR</b>（纽约证券交易所股票代码：XPEV）表示，尽管半导体短缺，但10月份仍交付了10,138辆汽车，同比激增233%。小鹏汽车股价在盘后交易时段上涨 0.4%，至 46.80 美元。</li><li>分析师预计<b>麦克森公司</b>（纽约证券交易所股票代码：MCK）最新季度每股收益为 4.62 美元，营收为 631.2 亿美元。该公司将在 clsoe 上市后发布收益。McKesson 股价周五上涨 1.4%，收于 207.88 美元。</li></ul><ul><li>开场钟声过后，<b>高乐氏公司</b>（纽约证券交易所股票代码：CLX）预计季度收益为每股 1.03 美元，营收为 17.0 亿美元。高乐氏股价在盘后交易中上涨 0.1%，至 163.10 美元。</li><li>分析师预计<b>安森美半导体</b>（纳斯达克股票代码：ON）公布季度收益为每股 0.74 美元，开盘前营收为 17.1 亿美元。安森美半导体股价在盘后交易中上涨 1.8%，至 48.94 美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PCG":"太平洋煤气电力","ON":"安森美半导体","XPEV":"小鹏集团"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2180275337","content_text":"Some of the stocks that may grab investor focus today are:\n\nWall Street expects PG&E Corporation  (NYSE:PCG) to report quarterly earnings at $0.26 per share on revenue of $5.37 billion before the opening bell. PG&E shares rose 0.6% to $11.67 in after-hours trading.\nXpeng Inc - ADR (NYSE:XPEV) said it delivered 10,138 vehicles in October, a 233% surge year-on-year, despite the semiconductor shortage. Xpeng shares rose 0.4% to $46.80 in the after-hours trading session.\nAnalysts are expecting McKesson Corporation  (NYSE:MCK) to have earned $4.62 per share on revenue of $63.12 billion for the latest quarter. The company will release earnings after the markets clsoe. McKesson shares rose 1.4% to close at $207.88 on Friday.\n\n\nAfter the opening bell, Clorox Co  (NYSE:CLX) is projected to post quarterly earnings at $1.03 per share on revenue of $1.70 billion. Clorox shares gained 0.1% to $163.10 in after-hours trading.\nAnalysts expect ON Semiconductor Corp  (NASDAQ:ON) to post quarterly earnings at $0.74 per share on revenue of $1.71 billion before the opening bell. ON Semiconductor shares rose 1.8% to $48.94 in after-hours trading.","news_type":1,"symbols_score_info":{"PCG":0.9,"ON":0.9,"XPEV":0.9}},"isVote":1,"tweetType":1,"viewCount":903,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600137171,"gmtCreate":1638085429516,"gmtModify":1638085506314,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Good and like&nbsp;","listText":"Good and like&nbsp;","text":"Good and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/600137171","repostId":"2186340224","repostType":4,"isVote":1,"tweetType":1,"viewCount":760,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":866910251,"gmtCreate":1632720722873,"gmtModify":1632798303739,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Good and like&nbsp;","listText":"Good and like&nbsp;","text":"Good and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/866910251","repostId":"2170108956","repostType":4,"isVote":1,"tweetType":1,"viewCount":600,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878272023,"gmtCreate":1637201529777,"gmtModify":1637201530016,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/878272023","repostId":"2184547718","repostType":4,"isVote":1,"tweetType":1,"viewCount":572,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":829172591,"gmtCreate":1633483643538,"gmtModify":1633483644067,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Good and like","listText":"Good and like","text":"Good and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/829172591","repostId":"1101968131","repostType":4,"isVote":1,"tweetType":1,"viewCount":448,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":883894411,"gmtCreate":1631231653833,"gmtModify":1631892300113,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/883894411","repostId":"2166426123","repostType":4,"isVote":1,"tweetType":1,"viewCount":602,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":873613723,"gmtCreate":1636936845454,"gmtModify":1636936845691,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Good and like&nbsp;","listText":"Good and like&nbsp;","text":"Good and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/873613723","repostId":"2183536049","repostType":4,"isVote":1,"tweetType":1,"viewCount":1109,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":840210035,"gmtCreate":1635648673953,"gmtModify":1635648674153,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/840210035","repostId":"1160516340","repostType":4,"repost":{"id":"1160516340","kind":"news","pubTimestamp":1635576015,"share":"https://www.laohunote.com/m/news/1160516340?lang=zh_CN&edition=full","pubTime":"2021-10-30 14:40","market":"sh","language":"en","title":"5 Stocks For Halloween: Will They Be Tricks Or Treats?<blockquote>万圣节的5只股票：它们会是骗局还是款待？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1160516340","media":"Benzinga","summary":"Halloween will be celebrated on Sunday and could see significant changes from the 2020 event in the ","content":"<p><div> Halloween will be celebrated on Sunday and could see significant changes from the 2020 event in the middle of a COVID-19 pandemic that saw many cancel parties and plans to trick or treat. Here’s a ...</p><p><blockquote><div>万圣节将于周日庆祝，在新冠肺炎疫情期间，许多人取消了聚会，并计划不给糖就捣蛋，与2020年的活动相比可能会发生重大变化。这是一个...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/news/small-cap/21/10/23762347/5-stocks-for-halloween-will-they-be-tricks-or-treats\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/news/small-cap/21/10/23762347/5-stocks-for-halloween-will-they-be-tricks-or-treats\">网页连接</a></blockquote></p><p></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks For Halloween: Will They Be Tricks Or Treats?<blockquote>万圣节的5只股票：它们会是骗局还是款待？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks For Halloween: Will They Be Tricks Or Treats?<blockquote>万圣节的5只股票：它们会是骗局还是款待？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga</strong><span class=\"h-time small\">2021-10-30 14:40</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> Halloween will be celebrated on Sunday and could see significant changes from the 2020 event in the middle of a COVID-19 pandemic that saw many cancel parties and plans to trick or treat. Here’s a ...</p><p><blockquote><div>万圣节将于周日庆祝，在新冠肺炎疫情期间，许多人取消了聚会，并计划不给糖就捣蛋，与2020年的活动相比可能会发生重大变化。这是一个...</div></blockquote></p><p>  <a href=\"https://www.benzinga.com/news/small-cap/21/10/23762347/5-stocks-for-halloween-will-they-be-tricks-or-treats\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://www.benzinga.com/news/small-cap/21/10/23762347/5-stocks-for-halloween-will-they-be-tricks-or-treats\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.benzinga.com/news/small-cap/21/10/23762347/5-stocks-for-halloween-will-they-be-tricks-or-treats\">Benzinga</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TR":"Tootsie Roll Industries Inc","JAKK":"杰克仕太平洋","CHCO":"City Holding Company","HSY":"好时","AMCX":"AMC网络公司"},"source_url":"https://www.benzinga.com/news/small-cap/21/10/23762347/5-stocks-for-halloween-will-they-be-tricks-or-treats","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1160516340","content_text":"Halloween will be celebrated on Sunday and could see significant changes from the 2020 event in the middle of a COVID-19 pandemic that saw many cancel parties and plans to trick or treat.\nHere’s a look at what the data is pointing to for 2021 Halloween spending and five stocks to keep on the radar that could turn in strong quarters that include the holiday.\nHalloween Sales Expectations:Consumers feel more comfortable resuming normal Halloween activities according to theNational Retail Federation.\n“This year, two-thirds (65%) of consumers plan to celebrate one of America’s favorite holidays, up from 58% in 2020,” NRF said.\nThe NRF sees consumers spending an average of $102.74 this year on Halloween, which would be the first time the figure has hit triple digits. Estimates last year were for spending of $92.12 by each consumer.\nResearch points to candy and costumes as big winners by the return of Halloween activities along with decorations. Spending on decorations is expected to hit $3.3 billion, an all-time high.\nIs Coca-Cola's Stock Overvalued OrUndervalued?\nHalloween 2021 will also see a higher number of people without kids celebrating than in 2020. Estimates call for 55% of homes without children to celebrate, compared to 49% in 2020. The figure falls in line with pre-pandemic levels of anticipated adult costume spending.\nTootsie Roll:Candy companyTootsie Roll Industries Inc\nTR-0.47%is a popular option for anyone handing out candy to trick or treaters. If you’ve ever gone trick or treating, chances are you got a ton of tootsie rolls, given their lower cost for anyone buying for a large number of visitors.\nThe companyreportedthird-quarter sales of $183.1 million, up 17% year-over-year. The company saw a dip in fourth-quarter revenue last year compared to the prior year. Look for Tootsie Roll to see a rebound in the fourth quarter.\nHershey:The Hershey Co\nHSY-2.28%has diversified its products to include several snack brands, but candy remains the big revenue driver. The company owns many of the popular brands that will be sought out by trick or treaters. Hershey’sthird-quarterrevenue of $2.4 billion was the highest it has seen in years on a quarterly basis.\n“Consumer demand for our brands has remained robust,” Hershey Company CEOMichele Bucksaid. The company raised full-year sales guidance and a strong Halloween could help meet or exceed the updated expectations.\nJakks Pacific:Toy companyJakks Pacific Inc\nJAKK-4.38%finds itself on the Halloween list thanks to its ownership of Disguise, the world’s leading costume design and manufacturing company. With more adults dressing up and a return of trick or treat activities, the company could be in for a strong quarter.\nThe company’sthird-quarterrevenue was $237 million, which included $64 million in revenue for the costumes segment. Costume sales were up 16.4% year-over-year and the fourth quarter could continue that trend. Jakks Pacific had revenue of $128.3 million in the fourth quarter last year, a decline from the prior year. Last year’s fourth quarter featured a 91% year-over-year increase in costumes segment revenue. The third and fourth quarters are the company’s two biggest quarters for revenue.\nParty City:Retailer$Party City Holdco(PRTY)$ Inc\nPRTY+2.97%could be a popular destination for Halloween costumes and decorations. The company ended thesecond quarterwith 749 locations and is also a provider of third-party products to other retailers.\nSecond-quarter revenue was up 110% year-over-year for the company.\n“We saw sequential acceleration of the business as the economy opened up and restrictions subsided, driving increased consumer ability to celebrate,” Party City CEOBrad Westonsaid. The company will report third-quarter earnings on Nov. 9, which could provide a better look at how the Halloween shopping looked.\nAMC Networks:Media companyAMC Networks\nAMCX-2.04%finds itself on the Halloween stock list thanks to its ownership of “The Walking Dead” franchise, horror film programming and as owner of horror focused streaming platform Shudder. AMC isairing“FearFest” from Oct. 1 through Oct. 31 on its namesake AMC and AMC+ channels, which could turn into a subscriber boosting event.\n“The Walking Dead” returned to the network with its final season beginning Oct. 10, which could be another October event to watch. Shudder, which is the largest horror focused streaming platform, is available for $4.75 a month on major streaming platforms. The platformhitone million subscribers in 2020. Pizza Hut, aYum Brands Inc\nYUM-0.75%company,partneredwith Shudder to offer a promotion for 30 days free.","news_type":1,"symbols_score_info":{"TR":0.9,"CHCO":0.9,"HSY":0.9,"AMCX":0.9,"JAKK":0.9}},"isVote":1,"tweetType":1,"viewCount":730,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":850027012,"gmtCreate":1634538156082,"gmtModify":1634538156649,"author":{"id":"4089205014499330","authorId":"4089205014499330","name":"SamYYL","avatar":"https://static.tigerbbs.com/c38b79dfd54364065e7068bc7e80dc9f","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089205014499330","authorIdStr":"4089205014499330"},"themes":[],"title":"","htmlText":"Good and like","listText":"Good and like","text":"Good and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/850027012","repostId":"2176421001","repostType":4,"isVote":1,"tweetType":1,"viewCount":699,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}